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One of the major focuses for our lab involves examining the immunosuppressive
properties of various agents and receptors in the experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis (MS). This dissertation
encompasses an investigation of cannabidiol in the EAE model, the endocannabinoid
CB1 receptor in the EAE model, staphylococcal superantigens (SAgs) as
immunosuppressive agents, and various aspects of the EAE model. The first chapter
covers the existing literature pertinent to these studies, the second and third chapters
cover the material, methods, and results from the studies, and the fourth chapter is a
discussion of how those results fit into the existing body of literature. A fifth chapter has
also been included which covers two additional studies designed to develop alternative
EAE models for our lab; however, both studies turned out differently than expected. One
of the most interesting developments from this final chapter was the discovery of an age

dependent difference in the memory T cell response of older mice, which allows for
more robust disease to be induced when cells from 6 month old mice are used in the
passive EAE (P-EAE) model as opposed to mice 10 weeks of age.
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CHAPTER I
SPECIFIC AIMS AND LITERATURE REVIEW
1.1

Specific Aims
One of the major challenges still left to be overcome in MS research involves the

development of effective treatment options for patients with MS. Many current
treatments for MS have undesirable side effects and few of them prevent the long term
progression of MS [1, 2]. The purpose of the studies outlined in this dissertation was to
explore the effects of various compounds, including cannabinoids and staphylococcal
SAgs, on the EAE model of MS, and to examine variations of the EAE model to better
understand how the pathogenesis of MS might be altered. We hypothesized that
through the use of cannabidiol (CBD), Cnr1-/- mice, and SAgs, and through the
exploration of variations of the EAE model, we would find novel methods of modulating
the EAE model of MS.
1.1.1

Specific Aim 1: Explore the effects of CBD on the EAE model
CBD is a phytocannabinoid which has been shown to be immunosuppressive in

a number of disease models including the EAE; however, its effect on the peripheral
immune response in the EAE model has yet to be fully explored [3-5]. The aim of these
studies was to examine the effect of oral CBD on peripheral inflammatory and
neuroinflammatory responses in the EAE model, with a specific focus on IFN-γ and IL1

17A producing T cells, regulatory T cells (Tregs) and myeloid derived suppressor cells
(MDSC) in the peripheral immune response at various time points. Here we used flow
cytometry, immunohistochemistry, and ELISAs to examine numerous inflammatory and
anti-inflammatory endpoints in both the peripheral and neuroimmune responses.
1.1.2

Specific Aim 2: Exploring the immunosuppressive properties of
Staphylococcus aureus SAgs
In previous studies, S. aureus SAgs have been shown to be immunosuppressive

in humans and cattle through the induction of regulatory cells, but the whether or not
SAgs can stimulate regulatory cell types in the murine immune system remains
unknown [6-8]. To determine if S. aureus SAgs possess ability to induce regulatory cells
in mice, we cultured splenocytes from C57BL/6 mice with various SAgs, and measured
the response of Tregs and MDSCs using flow cytometry.
1.1.3

Specific Aim 3: Explore the role of the CB1 receptor in the immune
response of the EAE model.
CB1 receptors have previously been shown to reduce clinical disease in the EAE

model through their neuroprotective and anti-spasmodic effects, yet the effects of the
CB1 receptor remain to be fully explored in the peripheral immune responses of this
model [9, 10]. In these studies we induced EAE in Cnr1-/- and WT littermates, and used
flow cytometry, ELISAs of serum and supernatants from ex vivo restimulated cells, and
a new histological scoring system developed by our lab to explore differences between
Cnr1-/- and WT mice. We also sought to confirm the results found in our ex vivo
restimulations with in vitro stimulations of splenocytes using anti-CD3/anti-CD28

2

antibodies and staphylococcal enterotoxin M (SEM) to specifically stimulate IFN-γ
production in T cells.
1.1.4

Specific Aim 4: Explore variations of the EAE model
There are several challenges associated with our EAE model which result in a

milder disease state compared to those previously reported by other labs. In light of this
our lab has been exploring the use of isoflurane to enhance our EAE model and the use
of other EAE models, like the P-EAE model, which will provide more robust disease and
allow us to explore the EAE model in a different way. Additionally, we have been able to
use the P-EAE model to further examine CBD’s effects on neuroinflammation and we
have discovered some age dependent differences in the P-EAE.
1.2
1.2.1

Literature review
Multiple sclerosis
MS is a progressive neurodegenerative autoimmune disorder of unknown

etiology that has been estimated to affect more than 2 million people around the world,
with more women being affected than men [11-13]. Current research suggests that
there are likely several components at play in the initiation of this disease, including
environmental, genetic, and immunologic factors [14, 15]. Although no one
environmental factor can fully explain the etiology of MS, a study examining the current
body of literature on environmental risk factors for MS determined that infection with the
Epstein - Barr virus, smoking, and infectious mononucleosis had the strongest evidence
for increasing the risk of contracting MS out of all the risk factors examined. The
mechanism by which these factors increase the risk for MS has yet to be shown. A
3

correlation was also found between increased distance from the equator and the
number of cases of MS, which has been supported by the assertion that decreased
levels of Vitamin D may contribute to the incidence of MS [15-17].
Much like the environmental risk factors, studies of the genetics behind MS have
revealed no one genetic factor that can explain the etiology of this disease; however, an
analysis of the genetic risk factors that contribute to MS by The International Multiple
Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium
showed that mutations in the human leukocyte antigen (HLA) genes coding for MHC
class II have a higher level of association with MS than any of the other single
nucleotide polymorphism (SNP) examined. This study also found that a significant
number of these SNPs are located in genes that affect T cell maturation, thus providing
strong evidence that dysregulation of the adaptive immune response is a key factor in
the initiation of MS [18].
Despite the widespread nature of MS, the current therapeutics options for MS
patients still do not provide complete relief of clinical disease, and are insufficient for
controlling the progressive phase of MS [1, 2]. In light of this, our lab has been working
on identifying new treatment methods for MS by using the EAE model. Highlighted in
the first four chapters of this dissertation are the results from an exploration of the
cannabinoid system as a target for treatment of MS, and the use of S. aureus
superantigens as potential immunosuppressive agents. Additionally, Chapter 5 outlines
the progress of we made in using the EAE model with isoflurane to enhance disease
and the P-EAE model.
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1.2.2

Clinical MS
Clinical symptoms of MS generally start in middle aged adults, and people who

develop this disease become progressively more disabled as the immune system
continues to attack the myelin sheaths of axons in the central nervous system (CNS)
[14, 19]. MS often includes a wide range of debilitating symptoms including cognitive
impairment, motor deficits, depression, epilepsy, focal cortical deficits, loss of vision,
tremors, loss of coordination and balance, diplopia, oscillopsia, vertigo, impaired
swallowing, impaired speech, emotional liability, weakness, stiffness, spasms, bladder
dysfunction, erectile impotence, constipation, pain, fatigue, exercise intolerance, and
temperature sensitivity [15]. MS can be categorized into one of three different types:
relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or secondary
progressive MS (SPMS). RRMS begins with an event known as the clinically isolated
syndrome (CIS), which is simply the first episode of neurologic dysfunction the patient
experiences. Approximately 85% of the individuals who experience CIS will continue to
have more episodes of neurologic dysfunction with periods of remission, and at this
point they are considered to have RRMS. RRMS is the most common form of MS [15,
19]. SPMS occurs 10 to 20 years after the patient is initially diagnosed with RRMS and
consists of a period of time where disease progression is continual due to a decrease in
brain volume and loss of functional axons. PPMS is similar to SPMS, except there is not
a RRMS phase preceding it [19]. Interestingly, studies examining incidence rates in MS
patients showed that RRMS has a higher sex bias towards women than PPMS,
however the reason for this bias is still unknown [12, 13].

5

1.2.3

Pathogenesis of MS
Initially Th1 cells were thought to be the driving force behind MS, but most of the

current literature provides evidence that Th17 cells might be a more important
component in disease initiation than Th1 cells. This idea was first suggested by an EAE
study in which adoptive transfer of Th17 cells was shown to be more pathogenic than
adoptive transfer of Th1 cells. This study also showed that mice lacking IL-23, an
important factor in the proliferation of Th17 cells, developed less severe clinical disease,
had fewer Th17 cell migrate into the CNS, and had a similar number of Th1 cells
migrate into the CNS as compared to wild type mice. These results suggest IL-23 and
Th17 cells play an important role in EAE pathogenesis, but are not critical for infiltration
of Th1 cells into the CNS [20]. This finding sparked a search for this newly discovered
pathogenic T cell in MS patients, and it was determined that Th17 cells are present in
higher numbers in the CNS during active MS than in either disease remission or healthy
individuals [21, 22].
In MS, autoreactive T cells enter the CNS and drive a neuroinflammatory
response by secreting a host of cytokines and chemokines that recruit other immune
cells to the CNS. In early MS, lesions in the CNS are predominated by macrophages
and CD8+ T cells, and to a lesser extent CD4+ T cells, B cells, and plasma cells. These
CD8+ T cells appear to be derived from a small number of progenitor cells, and the
number of CD8+ T cells found in white and gray matter lesions correlates closely with
axonal damage [19, 23]. This differs from the murine EAE model in that lesions primarily
contain macrophages and CD4+ T cells [19, 24]. In active lesions, macrophages and
microglia are primarily responsible for the breakdown of myelin sheaths and
6

oligodendrocytes within the CNS, which is thought to be the cause of many of the
symptoms seen in RRMS; however, they are also capable of reactivating autoreactive T
cells. Fortunately, myelin sheaths have some ability to regrow with time, so the patient
recovers much of their neurologic function when they go into remission. Nevertheless,
there is a far more insidious process that underlies the inflammation of a relapse, and
that is axonal degeneration. Gradual loss of neurons to axonal degeneration occurs as
a consequence of the demyelination process and is generally believed to be responsible
for the occurrence of SPMS and PPMS later in the patient’s life [19, 25, 26]. As MS
transitions into chronic inflammation, the number of infiltrating cells decreases, and in
SPMS, tertiary lymphoid structures that resemble B cells follicles can form in the
meninges of the CNS. These structures contain B cells, T cells, plasma cells and
dendritic cells, and are believed to be capable of generating inflammatory responses
within the CNS [19, 27].
An interesting dichotomy that forms in MS and EAE is the apparent conflict seen
between the proinflammatory and the anti-inflammatory branches of the immune
system. One example of this is seen in how macrophages and microglia respond during
neuroinflammation. As described above, microglia and macrophages are responsible for
activation of T cells and demyelination; however, once macrophages and microglia
phagocytize myelin they transition to a more immunosuppressive state. This change in
response to myelin is thought to contribute to remission in RRMS [25, 26]. Similarly, B
cells have both a pro-inflammatory role and an anti-inflammatory role in MS and EAE.
On the one hand, B cells contribute to inflammation through the production of antibodies
and their presence in tertiary lymphoid structures, but B cells producing the anti7

inflammatory cytokine IL-10 have been shown to have a suppressive role in EAE and
are elevated in MS patients [28]. The apparent duality of these various cell types may at
first seem counterintuitive, but in the context of clinical MS they might actually make
sense. If the initiation of a relapse is triggered by one cell type that causes a ripple
effect through the rest of the immune system, and all other cell types eventually convert
to an anti-inflammatory phenotype to block the overwhelming autoimmune response, it
could explain why there is a relapsing-remitting pattern to MS. Interestingly, the Tregs of
MS patients appear to be an exception to this rule. Despite some disagreement on
whether or not the number of Tregs is increased in the cerebral spinal fluid (CSF),
several studies report that Tregs from MS patients have decreased functionality, leading
some to speculate that MS may be, at least in part, due to a defect in the Treg system
[29-31].
1.2.4

EAE and P-EAE
Our lab uses two different methods of inducing EAE. The method we use most

frequently is initiated by immunizing C57BL/6 mice with Complete Freund’s Adjuvant
(CFA) containing Heat Killed Mycobacterium tuberculosis (HKMT), and myelin
oligodendrocyte glycoprotein (MOG) peptide. This causes the proliferation of Th1 and
Th17 cells specific to MOG peptide, which is found on the myelin sheaths of axons in
the CNS. As part of this MOG specific response cells begin trafficking across the blood
brain barrier (BBB) and targeting oligodendrocytes, which are the myelinating cells of
the CNS [32]. In addition to inflammatory cells, suppressor cells such as MDSCs and
Tregs also become activated, and have a suppressor role in the immune response
through various mechanisms. (Figure 1.1)[33, 34]. This method EAE induction is often
8

referred to as active EAE (A-EAE), however throughout this dissertation we will simply
refer to this method as EAE.
The second type of EAE induction that our lab uses is the P-EAE model. We induce PEAE by first initiating EAE in 2D2 transgenic C57BL/6 mice, which have a T cell
receptor (TCR) specific for MOG35-55 peptide on the majority of their CD4+ T cells. After
immunization, cells from the lymph nodes and spleens of the 2D2 transgenic mice are
restimulated ex vivo with MOG35-55 and transferred to WT mice to confer EAE to the
recipient mice. This method of induction is very useful for examining the later stages of
the immune responses in the absence of the overwhelming response to CFA and HKMT
that is present in active EAE.
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Figure 1.1

Breakdown of the BBB during EAE initiation

Presentation of MOG35-55 peptide to naïve T cells in the presence of IL-23, IL-6, TGF-β
and IL-1β, or IL-12 and IFN-γ generates pathogenic MOG specific Th17 and Th1 cells
respectively [32]. These cells then use various mechanisms to increase BBB
permeability, including the production of GM-CSF by Th17 cells and production of IFN-γ
by Th1 cells. GM-CSF and IFN-γ both have the ability to activate microglia and
macrophages, while GM-CSF reduces the expression of claudin-5 and
zonula occludens-1, which play an important role in the function of the tight junctions of
the BBB [35, 36]. Additionally, suppressor cells, such as Tregs and MDSCs, become
activated through the immunization process, and these cells have been shown to
suppress effector T cells through various mechanisms [33, 34].

1.2.5

Cannabidiol
CBD is a phytocannabinoid found in plants of the Cannabis sp. and is similar in

structure to the psychoactive phytocannabinoid Δ9-tetrahydrocannabinol (THC) (Figure
10

1.2). However, unlike THC, CBD possesses low affinity for CB1 (Ki ≥ 4.35µM) and CB2
(Ki ≥ 2.86µM) receptors, so it does not produce the psychoactive properties associated
with the activation of the CB1 receptor in the CNS. On the other hand, some evidence
shows that CBD does have the ability to antagonize the CB1 and CB2 receptor at lower
concentrations in a non-competitive manner, so some of its immunosuppressive actions
may still be mediated by the cannabinoid receptors [3, 37, 38]. Several other putative
targets of CBD have also been suggested, which include the Adenosine A2A receptor,
GPR55 orphan receptor, peroxisome proliferator-activated receptor γ (PPARγ), opioid
receptors, calcium channels, and metabolic enzymes of the Cytochrome P450 and
Glutathione pathways [37]. After oral and intraperitoneal (i.p.) dosing in mice, CBD has
been shown to readily distribute into the plasma and CNS, but CBD concentrations drop
below detectable levels by 24hr after oral and i.p. administration [39].
One of the properties of the phytocannabinoids which has drawn a great deal of
interest from the scientific community is their immunosuppressive capabilities. CBD has
shown promising anti-inflammatory capabilities in animal models including: EAE,
collagen-induced arthritis (rheumatoid arthritis model), carrageenan induced edema,
croton oil-induced hypermotility (inflammatory bowel disease model), and
pneumococcal meningitis [3]. However, it should be noted that there have been a few
reports showing that CBD may actually be pro-inflammatory under certain conditions.
More specifically, CBD was shown to increase IL-2 and IFN-γ production by suboptimally stimulated splenocytes from C57BL/6 mice, which corresponded to increased
translocation of nuclear factor of activated T cells (NFAT)[40]. Another study also
showed that CBD increased the lipopolysaccharide (LPS) driven inflammatory response
11

in the lungs of C57BL/6 mice, and increased the mRNA for several proinflammatory
cytokines within the lungs[41]. Although it remains unclear why CBD may be
proinflammatory under some conditions, these studies do show that there is still much
to learn about the use of cannabinoids as immunosuppressive agents.
While the number of explorations into CBD’s ability to combat clinical disease
and neuroinflammation in the EAE model are currently limited, the results have been
promising so far. A study by Kozela et al. in 2011 showed that activation of microglia
and invasion of T cells into the parenchyma of the spinal cord were greatly reduced
when mice were treated at the first sign of disease for 3 consecutive days with i.p.
injections of CBD [5]. Then in 2013 a study using the Theiler’s murine encephalomyelitis
virus (TMEV) model of MS showed that i.p. injections of CBD at the initiation of disease
significantly decreased leukocyte invasion into the CNS, vascular cell-adhesion
molecule-1 (VCAM-1) expression at the BBB, cytokine and chemokine expression, and
microglial activation [4]. In addition to these studies, clinical trials of the drug Sativex, an
oral mixture of THC and CBD, have shown efficacy in treating spasticity and
neuropathic pain in MS patients. However, clinical trials of oral CBD alone in MS are
currently lacking, and clinical trials of Sativex failed to prevent relapses from occurring
[37]. Given the potential benefits seen with CBD in other disease models, it is
imperative that its ability to treat MS be explored more completely. Some of the work
covered in the following chapters shows a potential link between CBD and inhibition of
IFN-γ production by T cells, and the subsequent suppression of the neuroimmune
response in the EAE model. These results are consistent with data from Kaplan et al.
which show the ability of CBD to suppress in vitro production of IFN-γ and IL-2 in
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splenic T cells when stimulated with phorbol 12-myristate-13-acetate and ionomycin
(PMA/Io) [42, 43].

Figure 1.2

Structure of THC vs CBD

THC is a tricyclic compound with a planar conformation, but CBD is a bicyclic
compound with free rotation around the C-C bond between the two rings which results
in a non-planar conformation.

1.2.6

Cannabinoid receptors
The cannabinoid receptors, CB1 and CB2, are G-protein coupled receptors of the

subtype Gi/o. Activation of these receptors influences several intracellular pathways,
including the production of cyclic AMP (cAMP) by adenylyl cyclase and activation of
mitogen-activated protein kinases (MAPK) [44]. The ability of the cannabinoid receptors
to act through these various pathways can cause a wide range of effects including but
not limited to: hyperpolarization of neurons, inhibition of neurotransmitter release,
changes in neuronal structure, modulation of intracellular calcium levels, modulation of
nitric oxide (NO) production, modulation of cytokine production, and increased migration
of various immune cells. With this wide range of potential responses, it is obvious why
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the use of cannabinoids as treatment options is such a complex area of research [44,
45].
CB1 and CB2 receptors have the potential to be both neuroprotective and antiinflammatory in MS, as has been shown using EAE models [9, 10]; however, it is
unclear to what extent these two receptors are involved in regulation of the
neuroimmune response. EAE models are commonly used to study the pathophysiology
of MS, and although they do not provide a perfect replica of the clinical progression in
humans they have been critical for advancing MS therapies [19]. Previous studies of the
CB1 receptor have suggested that it is primarily responsible for the neuroprotective and
antispasmodic affects seen with CB1/CB2 antagonists in ABH mice with EAE, while the
CB2 receptor is primarily responsible for immunosuppressive effect of these compounds
[9, 10, 46]. These results coincide with the fact that the CB1 and CB2 receptors reside
predominately in the brain and peripheral immune system respectively, but do not
account for the effects of the CB1 receptor in the peripheral immune system or CB2
receptor in the CNS [47-50].
With phytocannabinoids, such as the THC:CBD mixture Sativex, showing more
and more promise in clinical trials with MS patients, it becomes more important to fully
elucidate the mechanisms of these compounds and the receptors through which they
act [51-55]. In the studies outlined in this dissertation we use C57BL/6 Cnr1-/- and wild
type (WT) littermates to explore the effects of the CB1 receptor in the peripheral immune
response of EAE. This work represents an important step into understanding the how
CB1 receptors influence IFN-γ production during inflammatory responses, and provides
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more insight into how therapies designed to target CB1 receptors might alter peripheral
immune responses.
1.2.7

Staphylococcus aureus superantigens
S. aureus is a Gram positive facultative aerobe, and despite the fact that it is a

commensal organism in humans, under the right conditions it is capable of causing
serious disease [56]. One mechanism by which S. aureus causes disease is through the
release of SAgs, which cause a potent immune response by nonspecifically crosslinking
major histocompatibility complex (MHC) class II molecules on antigen presenting cells
(APC) to Vβ domain of TCRs. This crosslinking results in a nonspecific proliferative T
cell response, activation of the APC, and the release of pro-inflammatory cytokines. [56,
57] Since superantigens interact with the Vβ domain of TCRs, it was traditionally
thought that T cell stimulation occurs in both the CD4+ and CD8+ cell lines; however,
there is some evidence that shows in vivo T cell stimulation by SAgs is more specifically
directed towards the CD4+ T cells [57]. Analysis of the binding of SAgs to HLA-DR
molecules has revealed that there are two main sites on the MHC class II molecules to
which SAgs bind. SAgs can either bind with low affinity to the α chain of MHC class II or
with high affinity in a zinc dependent manor to the β chain of MHC class II [57]. As a
result of the immune response to SAgs, individuals may experience a wide range of
clinical signs, with one of the most severe being toxic shock syndrome [58, 59].
In more recent years there has been an increase in evidence suggesting that
SAgs may also have an immunosuppressive role in cattle and humans, both of which
possess S. aureus as a commensal organism [6-8]. In humans SAgs are able to
increase the number of functional CD25+FoxP3+ inducible Tregs (iTreg) in the
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peripheral blood mononuclear cell (PBMC) population. The conversion of CD25 - T cells
to iTregs was shown to be dependent on the presence of APCs and the activation of T
cells through the Vβ domain of the TCR [6]. In cattle, immunization with S. aureus
causes the upregulation of CD8+ T cells expressing the activation molecules ACT2 and
ACT3, which in turn suppress the response CD4+ T cells to both lectins and antigens [7,
60]. ACT3 is analogous to CD26 in humans, which has also been shown to be
increased in CD8+ T cells that can suppress CD4+ T cells in humans [61]; however, it
remains unclear whether ACT3 molecules are directly responsible for the suppression
of CD4+ T cells or if they are simply a sign that the CD8+ T cells have become activated.
The goal of the work done involving S. aureus SAgs in this dissertation was to
characterize the murine regulatory T cell response to various staphylococcus SAgs,
including several staphylococcal enterotoxins (SEs) and toxic shock syndrome toxin-1
(TSST-1). This work was done in collaboration with Dr. Keun Seo at Mississippi State
University as part of a species comparison between humans, cattle, dogs, and mice. As
part of this comparison, we also investigated the effects of various SAgs on the MDSC
populations, since one study found that mice chronically infected with S. aureus
developed a strong MDSC response in addition to a less robust Treg response [62].

16

CHAPTER II
MATERIALS AND METHODS
2.1

Reagents
CBD was provided by the National Institute on Drug Abuse. MOG 35-55 peptide

(MEVGWYRSPFSRVVHLYRNGK) was obtained from Biosynthesis (Lewisville, TX).
HKMT was purchased from Difco/BD Biosciences (Detroit, MI). CFA was obtained from
Sigma (St. Louis, MO). S. aureus SAgs were provided by Dr. Keun Seo of Mississippi
State University, College of Veterinary Medicine.
2.2

Animals
Experiments were approved by Mississippi State University Institutional Animal

Care and Use Committee (IACUC). WT female C57BL/6 mice obtained from Envigo
(Indianapolis, IN) at 8 weeks of age, ≥8 week old WT and Cnr1-/- C57BL/6 littermates
bred at Mississippi State University College of Veterinary Medicine, 2D2 TCR
transgenic mice obtained from Jackson Laboratories at 8 weeks of age, and FoxP3GFP
transgenic mice obtained from Jackson Laboratories at 8 weeks of age were used in the
experiments outlined in this dissertation. Mice were housed five to a cage at most in a
temperature (22°C±1°C), humidity (40-60%), and light (12h light: 12h dark) controlled
room. Food and water were provided ad libitum. As EAE progressed, access to water
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was ensured with use of long sipper tubes and food pellets were placed on the floor of
the cage after day 7 for EAE and from day 1 for P-EAE.
2.3

EAE induction and clinical assessment
C57BL/6 mice were immunized with 100 µl of CFA containing either 100 µg of

MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) with 0.5 mg of HKMT or 20 µg of
MOG35-55 peptide with 0.1 mg HKMT to induce EAE and Mild EAE, respectively. Control
mice were injected with saline. To perform the injections, mice were anesthetized with
3% isoflurane, and immunizations were given subcutaneously over the shoulders and
hips (25µl at each site), after which the mice were allowed to recover in a portion of the
cage cleared of bedding. For all studies involving CBD, starting 24 hr after the injections
were administered, mice were dosed each morning with either 75mg/kg of CBD in 100
µl of corn oil (CO) or 100 µl of CO for 5 days via oral gavage. This dose of CBD has
been used in previous studies and results in serum concentrations of CBD similar to
that found in humans [41]. Throughout this dissertation, EAE is often referred to as
“active EAE” to differentiate it from P-EAE induction discussed in Chapter 5; however, it
should be noted that if the term “EAE” is used it specifically refers to active EAE.
Clinical scores were recorded for each experiment using the following clinical
scale: 0 – Healthy; 0.5 – Flaccid tail; 1 – Hind limb paresis; 1.5 – waddling gait; 2 –
Unable to prevent being placed in dorsal recumbency; 2.5 – Hind limb dragging; 3 –
Single hind limb paralysis; 3.5 – Single hind limb paralysis with other hind limb dragging;
4 – Complete hind limb paralysis; 5 – Moribund/involvement of forelimbs. Mice were
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never allowed to progress past the clinical score of 4 for animal welfare purposes.
(Modified from Rao et al.) [63].
2.4

Cell cultures

2.4.1 Ex vivo restimulation with MOG peptide
Ex vivo restimulations of leukocytes from secondary lymphoid organs of EAE
mice is a method that our lab uses to examine the MOG35-55 specific peripheral immune
response, which can be measured using flow cytometry of cells and ELISAs of
supernatants. For all ex vivo restimulations, cells were isolated from the secondary
lymphoid tissues by mechanical disruption of individual spleens and lymph nodes in 1X
RPMI, followed by filtration using a 70 µm filter to obtain a single cell suspension. For
the CBD study, prior to restimulation, a portion of these isolates were set aside to stain
for the presence of Tregs and MDSCs as described below. In the CBD study, 1 x 106
cells were seeded into 96 well U-bottom plates in 200 µl of 1X RPMI supplemented with
5% bovine calf serum (BCS; HyClone, Logan, UT), 1% penicillin/streptomycin
(Pen/Strep; Gibco, Gaithersburg, MD), and 50 µM 2-mercaptoethanol (2-ME, Gibco)
and restimulated with 100 µg/ml of MOG35-55 peptide for 48 hr at 37°C; however it was
later determined that seeding 20 x106 cells into 4ml of complete media in a 6 well plate
with 50 µg/ml of MOG peptide was more effective at restimulating cells, so for the Cnr1-/vs WT studies this set up was used. At 44 hr, supernatants were collected for ELISAs,
and cells were resuspended in 1x RPMI containing 5µg/ml of Brefeldin A (BioLegend,
San Diego, CA) for the last 4 hr. Cells were then stained for extracellular markers (CD4
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and CD8) and intracellular cytokine production (IFN-γ and IL-17A) and analyzed using
flow cytometry.
2.4.2

Isolation of mononuclear cells from the spinal cords
To examine the infiltration of various T cells into the CNS, we isolated leukocytes

for analysis by flow cytometry. To isolate cells from the spinal cord of each mouse, the
spinal column was first removed and PBS was injected into the caudal aspect of the
spinal canal. This caused extrusion of the spinal cord from the cranial spinal canal,
which makes the spinal cord easier to process for the mononuclear cell isolation. The
spinal cord of each mouse was then cut into small pieces and digested with 1mg/ml
collagenase type 4 (Worthington) and 20 µg/ml DNase I for 45 min at 37°C with
agitation. To isolate mononuclear cells the digestion solution was then pressed through
a 70 µm filter and resuspended in 30% Percoll. The 30% Percoll was then underlain
with 70% Percoll to form a gradient and centrifuged at 500 x g on low speed with no
brake for 20 min. The mononuclear cells were then gently removed from the buffy coat
layer, and washed in PBS twice before proceeding to staining and flow cytometry. To
ensure enough cells were obtained for analysis, cells from two mice were pooled before
staining for flow cytometry.
2.4.3 S. aureus SAg stimulation of suppressor cells
Splenocytes were isolated by mechanically disrupting the splenic capsule in
RPMI, and bone marrow cells were isolated by rinsing the inside of the femurs from
each mouse with sterile PBS. Cells were then centrifuged into a pellet at 500 x g for 5
20

min, and resuspended in RPMI containing 10% BCS, 1% Pen/Strep, and 50µM 2-ME.
Throughout these experiments the culture conditions varied by plate type, number of
cells, types of cells, duration of culture, and SAgs type in an attempt to optimize the
stimulation conditions for Treg and MDSC induction. Cultures were done in either 6 well
or 96 well plates for durations ranging from 1 to 5 days with shorter cultures typically
being used for MDSCs as compared to Tregs, and the SAgs used were SEC, SEG, SEI,
SEM, SEN, SEO, and TSST. Additionally, in some cultures TGF-β and IL-2 were used
in an attempt to further induce Treg proliferation.
2.5

In vitro anti-CD3/anti-CD28 and Staphylococcus superantigen stimulation
To generate a T cells specific response from splenocytes that could be compared

to the MOG35-55 specific responses from ex vivo restimulations, we chose to use antiCD3/anti-CD28 antibodies and SEM. 48 well plates were pre-coated with 200µl of antiCD3 antibody (BioLegend Clone 145-2C11) diluted in sterile PBS at 1µg/ml (1:1000) or
0.5 µg/ml (1:2000) for 1hr at 37°C prior to culture. Next, the wells were rinsed 3x PBS,
and anti-CD28 antibody (BioLegend Clone 37.51) was added to the wells immediately
prior to seeding 1x106 splenocytes isolated from male and female WT or Cnr1-/- mice in
1ml of RPMI supplemented with 5% bovine calf serum, 1% penicillin/streptomycin, and
50 µM 2-ME. The final concentrations of anti-CD28 antibody were 1µg/ml (1:1000) or
0.5 µg/ml (1:2000). Other wells were treated with either 1µg of SEM, 5µg of SEM, or
received no treatment (NT). SEM was chosen for these experiments based on
preliminary experiments which showed consistent stimulation of T cells from C57BL/6
mice. These cultures were then incubated at 37°C for 2 or 3 days, and stained for flow
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cytometry as described below. Supernatant from these cultures were taken for IFN-γ
ELISA to determine total production of IFN-γ within the stimulated cultures.
2.6

Extracellular and intracellular staining

2.6.1 IL-17A and IFN-γ producing T cells
After treatment with Brefeldin A, cells were centrifuged at 500 x g for 5 min and
the media was removed. The cells were then rinsed by suspending them in 200 µl of 1X
PBS, centrifuging at 500 x g for 5 min, and PBS was removed. To measure viability,
Fixable Viability Dyes (FVD) were used. For early studies (EAE/CBD study) we used 0.5
µl Pacific Blue Zombie FVD (BioLegend, San Diego, CA) in 200 µl of PBS, but later
studies (Cnr1-/- vs WT EAE study) used 0.1µl of Near IR (NIR) FVD (BioLegend) in 50 µl
of PBS. In each case, the FVD was added to each well and allowed to incubate for 30
min at 4°C. The cells were centrifuged again at 500 x g for 5 min and the FVD solution
was removed. Then the cells were rinsed 2x with PBS. To prevent non-specific Ab
binding, cells were incubated at room temperature (RT) for 15 min in 50 µl of flow
cytometry buffer (FC buffer, 1X Hank’s Buffered Saline Solution with 1% bovine serum
albumin, pH 7.4) containing 0.5 µl of Fc Block (purified mouse CD16/CD32, BD
Biosciences, Billerica, MA). Without removing the Fc Block from the wells, 50 µl of FC
buffer containing 0.3 µl of extracellular antibodies was added to each well and allowed
to incubate at RT for 30 min. For stains performed during the EAE/CBD study these
extracellular antibodies consisted of CD4-FITC (BioLegend Clone Gk1.5) and CD8αPE/Cy7 (BioLegend Clone 53-6.7); however during the Cnr1-/- vs WT EAE study these
antibodies included CD4-PE (BioLegend Clone RM4-4), CD8α-PE/Cy7 (BioLegend
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Clone 53-6.7), and CD3-FITC (BD Bioscience Clone 145-2C11). The plate was then
centrifuged at 500 x g for 5 min, the supernatants containing the antibodies were
removed, and a rinse step was performed with FC buffer.
To stain for intracellular cytokines in the EAE/CBD study, 200 µl of
fixation/permeabilization solution (eBioscience/ThermoFisher, San Diego, CA) was
added to each well in preparation for intracellular staining, allowed to incubate for 30
min at RT, and removed by centrifuging the plate and dumping off the supernatants. 50
µl of 1X permeabilization solution (eBioscience) containing 0.5 µl of intracellular IL-17AAPC (BioLegend Clone TC11-18H10.1) and 0.5 µl IFN-γ-PE (BioLegend Clone
XMG1.2) was added to each well, and allowed to incubate at RT for 1 hr. The
antibodies were then removed as before and the cells were resuspended in 200µl of FC
buffer for analysis by flow cytometry. This approach was later modified for the Cnr1-/- vs
WT EAE study. During these later studies, after the rinse step with FC buffer, the cells
were fixed by incubating them in BD Cytofix solution (BD Bioscience) for 15min, and
then rinsing them once with FC buffer and once with BD permwash buffer (BD
Bioscience).Then the cells were resuspended in BD Permwash buffer containing 0.5 µl
of IFN-γ-APC (BioLegend Clone XMG1.2) and allowed to incubate overnight at 4°C.
After incubation the cells were rinsed with FC buffer and resuspended in 300 µl of FC
buffer.
2.6.2 Tregs
Identification of Tregs from wild type mice
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Cells isolated from SAg stimulate cultures were first stained with Zombie Green
FVD as described above, while cells isolated directly from secondary lymphoid organs
for our CBD/EAE studies were directly suspended in 200 µl of FC buffer, and
centrifuged at 500 x g for 5 min to rinse the cells before blocking. As before, cells were
treated with Fc Block, and then extracellular antibodies were added and allowed to
incubate for 30 min at room temperature. 50 µl of FC buffer containing 0.3µl of CD4PE/Cy7 (BioLegend Clone GK1.5) and CD25-FITC (BioLegend Clone PC61) was added
for the CBD studies, and 0.3µl of CD4-PE/Cy7 (BioLegend Clone GK1.5) and CD25-PE
(eBioscience Clone PC61.5) was used for the SAg regulatory T cell studies. The
antibodies were then removed and cells were washed with FC buffer. For intracellular
staining, cells were incubated with 200 µl of fixation/permeabilization solution for 30 min
at RT. Next the fixation/permeabilization solution was removed, the cells were incubated
with 50 µl of 1X permeabilization solution containing 0.5 µl FoxP3-APC (eBioscience
Clone FJK-16s) for 1 hr at RT or overnight at 4°C, and then suspended in 200 µl of FC
buffer for analysis by flow cytometry.

Identification of Tregs from FoxP3GFP mice
The extracellular staining protocol for the identification of Tregs from FoxP3GFP
mice was the same as for the WT mice; however, since GFP fluorescence is detected in
the same channel as the Zombie Green FVD signal, Sytox Red dead cell stain
(ThermoFisher) was used in these mice. After the extracellular staining was completed,
Sytox in FCM buffer (1:100) was added to each sample and the samples were analyzed
by flow cytometry.
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2.6.3

MDSC
Cells isolated from SAg stimulate cultures were first stained with Zombie Green

FVD as described above, while cells isolated directly from secondary lymphoid organs
during the CBD/EAE studies were directly suspended in 200 µl of FC buffer, and
centrifuged at 500 x g for 5 min to rinse the cells before blocking. As before, cells were
treated with Fc Block, and then extracellular antibodies were added and allowed to
incubate for 30 min at RT. 50 µl of FC buffer containing 0.3µl of CD11b-APC
(BioLegend Clone M1/70), Ly6G-PE/Cy7 (BioLegend Clone 1A8) and Ly6C-PE
(BioLegend Clone HK1.4) was added. The antibodies were then removed and cells
were washed with FC buffer. The MDSCs were fixed using BD Cytofix and then
resuspended in 200 µl of FC buffer for analysis by flow cytometry.
2.6.4

Spinal cord infiltrates
The cells isolated from spinal cords were rinsed two times with PBS, as

described above, and then incubated for 30 min at 4°C in 50 µl of PBS containing 0.1 µl
NIR FVD. The cells were then rinsed twice with PBS and incubated for 15 min in 50 µl
of FC buffer containing 0.5 µl of Fc Block. Without removing the Fc Block from the wells,
50 µl of FC buffer containing 0.3 µl of CD45-Brilliant Violet 605 (BV605;Biolegend Clone
30-F11), CD4-FITC (BioLegend Clone Gk1.5), CD3-Pacific Blue (BioLegend Clone
17A2), CD8-PE/Cy7 (BioLegend Clone 53-6.7), and CD25-PE (eBioscience Clone
PC61.5) was added to each well and allowed to incubate at RT for 30 min. After this
incubation the cells were rinsed with FCM and 50 µl of fixation/permeabilization solution
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was added and allowed to incubate for 30 min at RT. Intracellular staining for FoxP3
was performed as described in the previous section.
2.7

Flow cytometry
Cells stained with intracellular and extracellular florescent antibodies were

analyzed using an ACEA Novocyte flow cytometer (ACEA Biosciences, San Diego, CA)
or BD FACS Calibur flow cytometer.
2.7.1

IL-17A and IFN-γ producing T cells
To determine the percentage of Th1, Th17, Tc1, and Tc17 cells from the MOG 35-

55 ex

vivo restimulated cultures, dead cells were initially excluded from analysis by

selecting cells that were not stained by Pacific Blue FVD. Doublets were then eliminated
based on side scatter characteristics (SSC-A/H) and forward scatter characteristics
(FSC-A/H). Lymphocytes were selected based on their FSC and SSC, and CD4+ and
CD8+ positive populations were selected. Once the CD4 + and CD8+ lymphocytes had
been identified, gates were set up to determine the percentage of these cells that
contained intracellular IL-17A and IFN-γ (Figure 2.1).
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Figure 2.1

Gating strategy for identifying Tc1, Tc17, Th1, and Th17cells in the CBD
EAE study.

Live cells were first selected based on lack of staining with Pacific Blue FVD dye, and
these cells were then passed through two singlet gates to eliminate any doublets.
Lymphocytes were then selected based on FSC and SSC characteristics and from this
population cells were subdivided into CD8+IFN-γ+, CD8+IL-17A+, CD4+IFN-γ+, CD4+IL17A+ lymphocytes population.
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2.7.2

Tregs

2.7.2.1

Cannabidiol study
To identify Tregs from the spleens and lymph nodes of mice from the CBD study,

lymphocytes were first selected using FSC and SSC gating, and doublets were then
eliminated based on SSC-A/H and FSC-A/H characteristics. Then CD4+ cells were
selected by expression of CD4. Once CD4+ Cells were identified, the percentage of
double positive CD25+Foxp3+ cells within the CD4+ population was determined (Figure
2.2).
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Figure 2.2

Gating strategy for identifying MDSCs and Tregs in the CBD EAE study.

To identify regulatory cells from the spleens of mice in the EAE CBD study, lymphocytes
first identified based on FSC and SSC characteristics, and then passed through two
singlet gates to eliminate any doublet formation. From this population Tregs were
identified as CD4+CD25+FoxP3+ lymphocytes, granulocytic MDSCs were identified as
CD11b+Ly6CloLy6G+ lymphocytes and monocytic MDSCs were identified as
CD11b+Ly6C+Ly6G- lymphocytes.
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2.7.2.2

SAg study
When live/dead staining was used in an experiment, dead cells were first

excluded from analysis, and then analyzed using FSC vs SSC gating was used to
identify lymphocytes. If no live/dead staining was used, the cells were first analyzed with
FSC vs SSC gating. Lymphocytes were selected using FSC and SSC gating, and CD4 +
cells were selected based on expression of CD4. From this population the percentage
of double positive CD25+Foxp3+ cells was identified (Figure 2.3).

Figure 2.3

Gating strategy for Tregs in SAg studies with FoxP3GFP mice

Live cells were first identified based on Sytox Red staining, and then lymphocytes were
identified based on FSC and SSC characteristics. Tregs from this population of live
lymphocytes were then identified as CD4+CD25+FoxP3+ cells.
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2.7.3

MDSCs
Cannabidiol study

2.7.3.1

To identify MDSCs isolated from the spleens of mice in the CBD study,
lymphocytes were first selected using FSC and SSC gating, and MDSC were identified
based on their expression of CD11b, Ly6C, and Ly6G extracellular markers. Monocytic
MDSCs and granulocytic MDSCs were differentiated based on their Ly6C and Ly6G
profiles. Granulocytic MDSC were identified as CD11b+Ly6C+Ly6G+ cells and monocytic
MDSC were identified as CD11b+Ly6C+Ly6G- (Figure 2.2).
SAg study

2.7.3.2

During our studies with S. aureus Sags, live cells were first identified using
Zombie Green FVD. From this population we identified granulocytic MDSC as
CD11b+Ly6C+Ly6G+ cells and monocytic MDSC as CD11b+Ly6C+Ly6G- (Figure 2.4).

Figure 2.4

Gating strategy for MDSCs in S. aureus SAg studies

Within the live cell population, which were identified based on Zombie Green FVD
uptake, granulocytic MDSC were identified as CD11b+Ly6CloLy6G+ cells and monocytic
MDSC were identified as CD11b+Ly6C+Ly6G- cells.
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2.7.4

Spinal cord infiltrates
As before, dead cells were excluded from analysis by selecting cells that were

not stained by NIR FVD, doublets were excluded by their SSC-A/H and FSC-A/H
characteristics, and lymphocytes were selected based on FSC and SSC gating.
CD45+CD3+ cells were then selected and subdivided base on their expression of CD4 +
and CD8+. Further gating of CD3+CD4+ T cells was performed to determine the number
of Tregs within the spinal cords based on their expression of CD25 and FoxP3.
2.8

ELISA
Immulon 4 HBX flat bottom plates were coated with purified mouse IL-17A

(BioLegend Clone TC11-18H10.1) or IFN-γ (BioLegend Clone AN-18) antibodies by
adding 100 µl of coating buffer (4.2g of NaHCO 3 in 500mls of DI water) containing the
desired antibody at a 1:500 dilution, and incubating the plate overnight at 4°C. The next
day the plates were washed three times with PBS containing 0.05% Tween 20 (PBST).
PBS containing 3% BSA (3% BSA-PBS) was placed in the plate for at least 1 hr at RT
to block non-specific binding, and then the plate was washed three times with PBST.
100 µl of recombinant IL-17A (BioLegend) and IFN-γ (BioLegend) standards were then
pipetted into their respective wells at increasing concentrations (7.8-4000 pg/ml or 7.88000pg/ml), and 50µl of supernatants obtained from the 48 hr cultures were pipetted
into each plate to measure the concentration of IL-17A and IFN-γ in each supernatant.
1:10 dilutions of all supernatants were prepared in the same manner to detect higher
ranges of these cytokines. 100 µl of 3% BSA-PBS was used as a blank control. The
plates containing the standards and supernatants were then incubated for 1 hr at RT,
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and subsequently washed three times with PBST. 100 µl of biotinylated IL-17A
(BioLegend) or biotinylated IFN-γ (BioLegend) antibodies in 3% BSA-PBS at a 1:500
dilution were added to their respective plates and incubated for 1 hr at RT. The plates
were next washed three times with PBST. 100 µl of HRP-Avidin (BioLegend) in 3%
BSA-PBS at a dilution of 1:500 was added to each well and incubated for 1 hr at RT,
and then the plates were rinsed three times with PBST. 100 µl of TMB substrate
(BioLegend) was added to each well and incubated until color development was
detected in the lowest standard, then the reaction was stopped with 100 µl of 2N
H2SO4, and optical density (OD) was measured at 450nm.
2.9

Processing of brains and spinal cords for histology
After the mice were euthanized, to make manipulation of the cranium and spinal

column easier, the spinal column was severed at the base of the skull just caudal to the
first cervical vertebra (C1), and the brain and spinal column were processed separately.
2.9.1 Brain
To remove the brain from the cranial cavity, the calvarium was removed, the
brain was elevated out of the cranial cavity, and sharp dissection of the cranial nerves
was performed to disconnect the brain from the skull. The brain was then cut along the
sagittal plane using a razor blade and the right half of the brain was placed in 10%
neutral buffered formalin (NBF) for fixation. Once fixation was complete, the brains were
embedded in paraffin wax blocks so that sections of the tissue could be cut for
histologic analysis.
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2.9.2 Spinal column
After the spinal column was separated from the skull, the excess tissue and ribs
were trimmed, and the caudal end of the spinal cord was cut at the level of the L6
vertebra. Next, the entire spinal column was placed in 10% NBF for fixation. The fixed
spinal columns were rinsed in PBS to remove the 10% NBF, and were placed in a 10%
EDTA solution at pH 7.4 for decalcification. 10% EDTA was made by diluting 0.5M
EDTA, pH 8 (ThermoFisher) with distilled water, and adjusting the solution to pH 7.4
with acetic acid. The spinal columns were left in this solution for 15 days and the
solution was refreshed every 5 days. Once decalcification was complete, the spinal
column was cut at the T7 vertebra to isolate the lumbar intumescence. This method of
dissection left the spinal column between T7 and L6. The T7-L6 region was then either
cut at intervals of approximately 0.3cm or 0.5cm depending on the study. The segments
were then embedded in a cranial to caudal orientation within paraffin wax blocks so the
tissue could be cut for histologic analysis.
2.10
2.10.1

Immunohistochemistry and histologic analysis
CBD study
5-µm sections of brains and spinal cords from each time point were initially

stained with hematoxylin and eosin (H&E) to determine the level of cellular invasion.
Based on the results seen from this initial analysis, it was determined that brains from
the day 18 mice in the SAL/CO, EAE/CO and EAE/CBD groups would be stained for

34

CD3 to determine which regions contained T cells, and spinal cords would be used for
quantification of T cell numbers and lesion size.
2.10.1.1

CD3 staining

5-µm sections from brains and spinal cords of the day 18 mice from SAL/CO,
EAE/CO and EAE/CBD groups were used for CD3 staining. Sections were first
deparafinized and rehydrated by placing them in the following solutions for 2 min each:
xylene, 100% ethanol, 95% ethanol, and DI water. Antigen retrieval was performed in a
steamer by treating the slides for 20 min with Target Retrieval Solution (TRS; Dako,
Santa Clara, CA) which is a modified citrate buffer with a pH 6.1. After retrieval, slides
were air dried for 10 mins, rinsed with phosphate buffered saline (PBS), and covered
with 3% H2O2 for 30 min to block endogenous peroxidases. H2O2 was removed by
washing the slides three times in PBS. A PBS solution containing 1% bovine serum
albumin (BSA) and 4% goat serum (Vector Laboratories, Burlingame, CA) was then
added to each slide and incubated for 1 hr to block non-specific binding of the primary
antibodies. The blocking solution was removed and polyclonal rabbit anti-human CD3
antibody in PBS/1% BSA/0.1% Triton X-100 (Tx) (1:2500; Dako) was added to each
slide and incubated overnight at 4°C. The following day, slides were rinsed three times
with PBS and treated with a biotinylated goat anti-rabbit secondary antibody diluted in
PBS/1% BSA/0.1% Tx (1:100; Vector Laboratories,) for 2 hr at RT. Slides were then
rinsed with distilled water three times, and incubated in a solution containing avidin D
and biotinylated horseradish peroxidase H (Vectastain Elite ABC Kit; Vector
Laboratories) in PBS for 2 hr. Sections were then rinsed three times with distilled water
35

and incubated with diaminobenzidine (DAB; Dako) for approximately 5 min. The
reaction with DAB was stopped by dipping the slides in distilled water, and the slides
were dipped in hematoxylin to make visualization of histologic structures easier. Each
slide was then dipped in 0.3% ammonia water to lighten the hematoxylin stain. For
dehydration, slides were dipped in each of the following solutions for 1 min: distilled
water, 75% ethanol, 100% ethanol, and xylene. A cover slip was placed on the slide
with permount and allowed to dry.
2.10.1.2

CD4 and CD8 double stain

Due to the extremely dim staining that resulted from CD4 immunofluorescent
staining, it was decided that the best route to achieve a double stain would be to stain
the CD4 first as an immunoperoxidase stain, and then follow up with a CD8
immunofluorescent stain. Much like the CD3 stain, slides for the double stain underwent
deparafinization, antigen retrieval and blocking with 3% H2O2; however, it is important to
note that 1% Tx was added to the antigen retrieval solution to help uncover the
antigens. Following the blocking step, a biotinylated monoclonal rat CD4 antibody in
PBS/1% BSA/1% Tx (1:40; ThermoFisher Clone 4SM95) was added to each slide and
allowed to incubate overnight at 4°C. The next day, the slides were rinsed with distilled
water and incubated in a solution containing avidin D and biotinylated horseradish
peroxidase H (Vectastain Elite ABC Kit; Vector Laboratories) and an unconjugated
monoclonal rabbit CD8 antibody in PBS (1:50; Abcam, Cambridge, MA Clone
EPR21769) for 2 hr at RT. Sections were then rinsed three times with distilled water and
incubated with DAB for approximately 20 min. The reaction with DAB was stopped by
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dipping the slides in distilled water, and the slides were dipped in hematoxylin to make
visualization of histologic structures easier. Each slide was then dipped in 0.3%
ammonia water to lighten the hematoxylin stain. Next an Alexa Fluor 488 conjugated
goat anti-rabbit IgG antibody in PBS/1% BSA/0.1% Tx (1:200; ThermoFisher) was
added to each slide and allowed to incubate for 2 hr. To protect the Alexa Fluor 488
from degradation during visualization, slides were coverslipped with Vectashield (Vector
Laboratories).
2.10.1.3

Glial fibrillary acidic protein (GFAP)

GFAP is a marker that is commonly used to identify activation of astrocytes
within the CNS. However, here we use this stain to delineate the boarder of the BBB so
that we can show measure the size of lesions within the BBB. Deparafinization, antigen
retrieval and blocking with 4% goat serum was performed as it was for the CD3 stain.
After blocking, slides were incubated with PBS/1% BSA/0.1% Tx containing
unconjugated polyclonal rabbit GFAP antibody (1:200; Millipore, Burlington, MA)
overnight at 4°C in the dark. The next day, the slides were rinsed in distilled water and
incubated for 2 hr with PBS/1% BSA/0.1% Tx containing Alexa Fluor 488 conjugated
goat anti-rabbit IgG antibody (1:200; ThermoFisher) and 0.5µg/ml of 4′,6-Diamidine-2′phenylindole dihydrochloride (DAPI; ThermoFisher) as a nuclear counterstain. Slides
were then rinsed and coverslipped with Vectashield.
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2.10.1.4

Iba-1 Staining

5µm sections of spinal cords from SAL/CO, EAE/CO, and EAE/CBD mice taken
on days 10 and 18 of the study were used for Iba-1 staining. Sections for the Iba-1
staining were first deparafinized and rehydrated by placing them through xylene, 100%
ethanol, 95% ethanol, DI water at 2 mins each. Antigen retrieval was performed by
placing the slides in TRS for 30mins in a steamer. The slides were then allowed to cool
for 10mins and rinsed in PBS. Non-specific binding was blocked by placing the sections
in PBS containing 1% BSA and 4% goat serum for 1hr at RT. The blocking solution was
then removed and polyclonal rabbit Iba-1 antibodies (anti-AIF-1; Millipore) were placed
on the sections in PBS/1% BSA/0.1% Tx. These slides were then incubated overnight at
4°C. The next day the slides were rinsed in distilled water to remove excess antibodies,
and incubated for 2 hr in PBS/1% BSA/0.1% Tx containing Alexa Fluor 488 conjugated
goat anti-rabbit IgG antibody (1:200). Slides were rinsed and coverslipped with
Vectashield before imaging.
2.10.1.5

Imaging and quantification

Images were captured using a Lumenera Digital Camera equipped with Infinity
Analyze Software, and analyzed using the ImageJ software. To analyze the number of
CD3+, CD4+, and CD8+ T cells present within the spinal cord a total of four lesions from
two sections of lumbosacral intumescence of each mouse were analyzed at 400 x
magnifications. The number of each cell type was averaged across the four lesions to
get the average number of cells for lesions within the lumbosacral region of each
mouse. To determine lesion size for each mouse, 40x magnification images of 2
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sections from the same region were analyzed using the GFAP/DAPI stain, which
allowed us to determine the size of the lesion within the parenchyma of the spinal cord
and exclude the portion of the lesions within the meninges.
Cnr1-/- vs WT study

2.10.2
2.10.2.1

Histologic scoring

Spinal cords were processed and each 0.5 cm section was embedded in a
cranial to caudal orientation within paraffin wax blocks to ensure 0.5 cm spacing
between subsequent sections (Figure 2.1 A&C).
In order to analyze neuroinflammation within the spinal cord a new scoring
system was developed to account for variations in lesion size, location along the spinal
cord, and location within a section. H&E stains of the first 5 sections of spinal cord from
each histologic preparation were used to generate histologic scores for each mouse.
Each section was first divided into four regions (Figure 2.1B) and then each region was
given a score based on the number of infiltrating cells within the largest lesion found in
that region. The possible scores given to each region were: 0 = no cells; 1 = 10 to 100
cells; 2 = 100 to 200 cells; 3 = 200+ cells. Microscopic images were captured using a
Lumenera Digital Camera and Infinity Analyze Software. Scoring and lesion area
calculations were done with ImageJ software.
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Figure 2.5

Histologic scoring system

The spinal column for each mouse was sectioned in to six 0.5 cm section and placed in
paraffin wax blocks so that the cranial aspect of each section would be cut first (A).
Then each of the quarter of the first 5 sections was given a score based on the number
of cells found within each quarter of the spinal cord (B). Representative H&E images of
the first 5 sections are shown (C).

2.11

Statistical analysis
Statistical analysis was done with GraphPad Prism 6 or GraphPad Prism 7

software. For clinical scoring and histological scoring the Mann-Whitney U test was
used for comparisons between groups. All other comparisons were done using ANOVA
or T-Test as appropriate. Transformations were performed on all percentages obtained
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by flow cytometry before ANOVA was performed. Graphical representations of data
show averages within each group and the error bars represent the standard deviation of
each group.
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CHAPTER III
RESULTS
3.1

Effects of oral CBD on the peripheral immune and neuroimmune response
The aim of these experiments was to examine the effects of oral CBD on the

peripheral and neuroimmune response using the EAE model. Using this model we were
able to induce disease in C57BL/6 mice, and oral CBD was administered for the first 5
days after the initiation of disease. Mice were euthanized on days 3, 10, and 18, and
lymph nodes, spleens, spinal cords and brains were used to examine the effect CBD
had on the EAE immune response.
3.1.1

Clinical scores
Average clinical scores recorded during the 18 day time course showed that

clinical disease began on approximately day 14 for all groups except for the SAL/CO
group (n=5). On day 18, the EAE/CO group (n=11) had the highest average clinical
score out of all the groups, with the EAE/CBD group (n=11) having a significantly lower
average clinical score than the EAE/CO group. The Mild EAE/CO group (n=5) also had
a significantly lower average clinical score as compared to the EAE/CO group. There
was no significant clinical difference seen between the Mild EAE/CO and Mild EAE/CBD
(n=5) groups. The control group showed no signs of clinical disease (Figure 3.1).
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Figure 3.1

Effects of oral CBD in EAE clinical scores.

Average clinical scores recorded for each group of mice during the 18 day time course.
Mice from 3 and 10 day time points were included in each group until they were
euthanized. Disease incidence in day 18 groups was as follows: SAL/CO = 0% (n=5),
EAE/CO = 81.82% (n=11), EAE/CBD = 63.64% (n=11), Mild EAE/CO = 60% (n=5), Mild
EAE/CBD = 40% (n=5). * p < 0.05 differences between SAL/CO and EAE/CO; # p <
0.05 difference between EAE/CO and EAE/CBD; @ p < 0.05 difference between
EAE/CO and Mild EAE/CO.

3.1.2

Effects of CBD on suppressor cell populations
Same day analysis by flow cytometry of suppressor cells isolated from the

secondary lymphoid tissue showed that treatment with CBD did not significantly change
the percentage of Tregs isolated from the lymph nodes and spleen, or MDSCs from the
spleen (Figure 3.2). However, significant increases were seen in the percentage of
MDSCs recovered from the spleens of EAE and Mild EAE mice as compared to the
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SAL/CO group at several time points with the most pronounced differences being seen
on day 10 (Figure 3.2C-D). Significant decreases were also seen in the percentage of
Tregs recovered from the spleens and lymph nodes of the EAE/CO and Mild EAE/CO
groups. On day 10, a lower percentage of Tregs was recovered from the lymph nodes
of EAE/CO and Mild EAE/CO groups as compared to the SAL/CO group, and the
percentage of Tregs recovered from the spleens of the EAE/CO mice was significantly
decreased as compared to the SAL/CO group and the Mild EAE/CO group (Fig. 3.2AB). Lastly, a significant decrease was found in percentage of monocytic MDSCs present
in splenocytes from Mild EAE/CBD as compared to the EAE/CBD group on day 10 (Fig.
3.2D).
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Figure 3.2

Regulatory cells from secondary lymphoid organs

Lymph nodes and spleens were taken from each mouse on the day of necropsy and
made into single cell suspensions by passing them through a 70µm filter. Cellular
isolates from the lymph nodes were then stained for the classic Treg markers
(CD4+CD25+FoxP3+)(A), and cellular isolates from the spleens were stained for Treg
markers (B), Granulocytic MDSC markers (CD11b +Ly6CloLy6G+)(C) or Monocytic
MDSC markers (CD11b+Ly6C+Ly6G-)(D). These cells were then analyzed using flow
cytometry to determine the percentage of regulator cells for each sample. n=5 for each
group of mice (SAL/CO, EAE/CO, EAE/CBD, Mild EAE/CO, and Mild EAE/CBD) on
each day. * p<0.05 differences between SAL/CO and EAE/CO; ‡ p<0.05 difference
between SAL/CO and Mild EAE/CO; @ p<0.05 difference between EAE/CO and Mild
EAE/CO; € p<0.05 difference between EAE/CBD and Mild EAE/CBD.
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Effects of CBD on IFN-γ and IL-17 producing T cells

3.1.3

Intracellular cytokine staining

3.1.3.1

Analysis of IFN-γ+ and IL-17A+ T cells after a 48 hr restimulation with MOG35-55
peptide showed significant differences in the percentage of MOG 35-55 specific IFN-γ
producing CD8+ T cells isolated from the spleens of day 10 mice (Fig. 3.3C). On this
day, EAE/CO had the highest percentage of IFN-γ producing CD8+ T cells as compared
to all other groups, with the SAL/CO, EAE/CBD, and Mild EAE/CO groups having a
significantly lower percentage than the EAE/CO group. Interestingly, this pattern was
also seen in the CD4+ T cells from the spleen, but only the difference between EAE/CO
and SAL/CO groups was significant. Lastly, the number IL-17A+CD8+ T cells isolated
from the spleen of EAE/CO mice on day 10 was significantly increased as compared to
the SAL/CO group. There were no effects of CBD on IL-17-producing T cells in the
spleen.
Analysis of IFN-γ+ and IL-17A+ T cells from the lymph nodes after a 48 hr
restimulation with MOG35-55 peptide revealed very low cytokine production at all time
points tested (Fig. 3.4A-D). There were no significant changes noted in response to
disease or CBD.
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Figure 3.3

Cytokine production in T cells isolated from spleens after ex vivo
restimulation.

Splenocytes were restimulated ex vivo with MOG35-55 peptide for 48 hr, and then treated
with Brefeldin A to block the secretion of cytokines. Cells were then stained for
expression of CD4, CD8, IFN-γ and IL-17A, and Flow cytometry was used to measure
the percentage of IFN-γ and IL-17A producing cells within the CD4 (A & B) and CD8 (C
& D) populations. n=5 for each group of mice (SAL/CO, EAE/CO, EAE/CBD, Mild
EAE/CO, and Mild EAE/CBD) on each day. * p<0.05 differences between SAL/CO and
EAE/CO; ‡ p<0.05 difference between SAL/CO and Mild EAE/CO; # p<0.05 difference
between EAE/CO and EAE/CBD; @ p<0.05 difference between EAE/CO and Mild
EAE/CO
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3.1.3.2

Cytokine production in supernatants
ELISAs were performed on the supernatants following 48 hr restimulation with

MOG35-55 peptide to determine the cumulative production of IFN-γ and IL-17A during
culture. In general, the cultured cells from EAE mice produced more IFN-γ and IL-17A
than Mild EAE groups, with this difference reaching significant levels within the cultured
splenocytes, and cytokine production was increased earlier in the lymph nodes than in
the spleen (Fig. 3.5A-D). There was also a significant increase in IFN-γ production in
EAE/CBD as compared to EAE/CO in splenocytes at day 18.
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Figure 3.4

Cytokine production in T cells isolated from lymph nodes after ex vivo
restimulation.

Cells isolated from lymph nodes were restimulated ex vivo with MOG 35-55 peptide for 48
hr, and then treated with Brefeldin A to block the secretion of cytokines. Cells were then
stained for expression of CD4, CD8, IFN-γ and IL-17A, and flow cytometry was used to
measure the percentage of IFN-γ and IL-17A producing cells within the CD4 (A & B)
and CD8 (C & D) population. n=5 for each group of mice (SAL/CO, EAE/CO, EAE/CBD,
Mild EAE/CO, and Mild EAE/CBD) on each day.
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Figure 3.5

ELISA of cytokines after ex vivo restimulation

After 48 hr restimulation of lymphocytes from secondary lymphoid tissues with MOG 35-55
peptide, the supernatants from these cultures were analyzed by ELISA for the total
amount of IFN-γ (A & B) and IL-17A (C & D). n=5 for each group of mice (SAL/CO,
EAE/CO, EAE/CBD, Mild EAE/CO, and Mild EAE/CBD) on each day. * p < 0.05
differences between SAL/CO and EAE/CO; # p < 0.05 difference between EAE/CO and
EAE/CBD; @ p < 0.05 difference between EAE/CO and Mild EAE/CO; € p < 0.05
difference between EAE/CBD and Mild EAE/CBD.
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3.1.4 Analysis of brain and spinal cord
3.1.4.1

Brain
H&E stains were performed on all mice to examine the level of cellular infiltration,

and it was determined that cellular infiltrates were primarily observable at day 18. H&E
stains of the brain from day 18 EAE/CO mice revealed cellular infiltrates throughout the
white matter tracts of the brain, with the highest levels of infiltration being consistently
seen in the white matter of the cerebellum. The infiltrating cells in the cerebellum of
EAE/CO mice were evenly spread throughout the white matter tracts, and there was
significant perivascular cuffing evident in these mice (Fig. 3.6B). Immunoperoxidase
staining for CD3 also revealed that a significant number of the infiltrating cells within
these sections were T cells (Fig. 6E and H). In contrast to this, the EAE/CBD group had
fewer cellular infiltrates and T cells within the white matter tracts of the cerebellum as
compared to the EAE/CO group, and the cells were localized primarily in the
perivascular cuffs with CBD treatment (Fig. 6C, F, and I). No cellular infiltrates or T cells
were observed in the SAL/CO group (Fig. 6A, D, and G).
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Figure 3.6

CBD reduces neuroinflammation in the cerebellum of EAE mice.

Brains from SAL/CO, EAE/CO and EAE/CBD mice on day 18 were embedded in
paraffin wax blocks and 5µm longitudinal sections of the cerebellums were examined
using H&E and CD3 stains. Images of H&E stains show increased cellular infiltration
into the white matter tracts of the cerebellum in EAE/CO mice (n= 5) as compared to
SAL/CO (n= 5) and EAE/CBD mice (n= 5) (A-C). Similarly, CD3 stains revealed a higher
level of T cell infiltrates in the EAE/CO group as compared to the SAL/CO and
EAE/CBD groups. CD3 stains are shown at 40x (D-F) and 200x (G-I) magnifications.
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3.1.4.2

Spinal cord
H&E stains were performed on all mice to examine cellular infiltration, and it was

determined that cellular infiltrates were present primarily at the day 18 time point. The
most prominent feature observed in the H&E stains of lumbosacral spinal cord from day
18 EAE/CO mice was the presence of subpial and perivascular cellular infiltrates that
were comprised largely of CD3+ T cells (Fig. 7B, E, and H). Subpial and perivascular
infiltration was also seen in the spinal cords of EAE/CBD mice, but to a lower extent
(Fig. 7C, F, and I). Double staining of the spinal cord for CD4 + and CD8+ T cells (Figure
7 J-R) from each group showed similar patterns of infiltration compared to those seen
with the CD3 stain. To maximize our ability to accurately analyze the T cell
compartment, quantifications of CD3+ cells were performed on the same lesions as the
quantifications for CD4+ and CD8+ cells in the next consecutive slice taken from the
paraffin blocks containing the spinal cords. No cellular infiltrates or T cells were
observed in the SAL/CO group (Fig. 7A, D, G, J, M, and P). Spinal cord sections were
also analyzed for lesion size using a GFAP/DAPI stain, which allowed for a more
accurate measurement of lesion size within the parenchyma by eliminating the cells that
were located in the meninges (Figure 8). As with the T cell stains, the GFAP/DAPI stain
showed a large amount of subpial and perivascular infiltration, but this stain also
highlights the boundary between meningitis and myelitis in these sections. An
observation that was of particular note in all of the stains that were performed was a
surprising lack of cellular infiltrates in the white matter of the nerve roots surrounding the
lumbosacral spinal cord. Quantification and statistical analysis of the T cells and lesions
of the spinal cords revealed a modest decrease in the number of T cells and size of the
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lesions in the EAE/CBD group as compared to EAE/CO group at the day 18 time point
(Figure 3.9 A-C). In contrast to this, staining of spinal cord sections from SAL/CO,
EAE/CO, and EAE/CBD mice from day 10 and day 18 for Iba-1 showed that microglial
activation was not affected by treatment with CBD in the day 18 mice (Figure 3.10). We
also found that microglial activation was not elevated above basal levels at the day 10
time point (Figure 3.10D).
Analysis of spinal cord infiltrates by flow cytometry
Flow cytometry performed on cells isolated from the spinal cord of EAE/CO and
EAE/CBD mice showed a modest reduction in the percentage of CD3+CD4+ T cells,
which closely resembled the results found by histologic analysis of the spinal cord
(Figure 3.9D). No difference was seen in the percentage of CD3 +CD8+ or
CD3+CD4+CD8+ T cells. Further analysis of CD25 and FoxP3 expression by CD4+ cells
also revealed very small numbers of Tregs present within the spinal cords of both
groups, and no significant difference was seen between groups (data not shown).
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Figure 3.7

CBD reduces neuroinflammation in the spinal cord of EAE mice

Spinal columns from SAL/CO (n=5), EAE/CO (n=5) and EAE/CBD (n=5) mice on day 18
were embedded in paraffin wax blocks and 5µm sections were examined using H&E,
CD3, CD4, and CD8 stains. Images of H&E stains showed increased cellular infiltration
around large blood vessels and in peripheral white matter tracts of the spinal cords of
EAE/CO mice as compared to SAL/CO and EAE/CBD mice (A-C). Similarly, CD3 stains
revealed a higher number of T cell in these regions in the EAE/CO group as compared
to the SAL/CO and EAE/CBD groups. CD3 stains are shown at 10x (D-F) and 40x (G-I)
magnifications. CD4 and CD8 double staining was performed on the next slice taken
from the paraffin blocks containing the spinal cords, thus allowing for intralesional
comparisons to be made between the number of CD3, CD4, and CD8 positive cells.
CD4 staining (J-L) revealed moderately lower numbers of CD4+ T cells present within
the lesions of the spinal cords, while CD8 staining (M-O) revealed no substantial
difference between the number of CD8+ T cells when comparing the EAE/CO and
EAE/CBD groups. To overcome the dark background of the CD8 immunofluorescent
stain in the combined CD4/CD8 images (P-R) the contrast of the original CD4 stains (JL) was enhanced by 0.2% using ImageJ software.
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Figure 3.8

Measuring lesion size within the parenchyma of the spinal cord

From the same paraffin wax blocks that were used for T cell staining, 5µm sections of
spinal columns from SAL/CO (n=5), EAE/CO (n=5) and EAE/CBD mice (n=5) on day 18
were stained for expression of GFAP to highlight astrocytes. By using an
immunofluorescent GFAP Stain (A-C & J) to define the boundary of the spinal cord
parenchyma created by the glial limitans, and a DAPI nuclear stain (D-F & K) to identify
lesions within the spinal cord, we were able to accurately determine total lesion area
within the parenchyma of spinal cord sections by overlaying images of the two stains
and removing cells within the meninges from consideration. Images were taken at 40x
magnification (A-I) and 200x magnification (J-L). Images J-L show the accumulation of
cells outside of the glial limitans around major vessels and help to illustrate the
difference between meningitis and myelitis.
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Figure 3.9

Quantification of T cells and lesion area within the spinal cord

A total of 4 lesions from the lumbosacral intumescence were analyzed for the number
and type of T cells present, as well as lesion size. CD3 (A) and CD4/CD8 double
staining (C) were done on consecutive slices from the paraffin blocks, which allowed for
intralesional comparisons to be made for the T cell counts. Quantification of T cells was
performed by counting the number of cells present within an image captured at 400x
magnification for each of the four lesions, and averaging the counts for each mouse.
Lesion area within the parenchyma of the spinal cord (B) was measured first outlining
the area of the lesion seen in the DAPI image, then overlaying the GFAP image and
adjusting the outline so that only cells within the parenchyma were considered (Figure
8). Analysis of spinal cord infiltrates by flow cytometry also revealed a moderate
increase in the percentage of CD3+CD4+ T cells within the spinal cord (D). * p < 0.05
differences between SAL/CO and EAE/CO
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Figure 3.10 The effects of CBD on microglial activation in the EAE model
5µm sections of spinal cords from SAL/CO (n=5) (A), EAE/CO (n=5) (B) and EAE/CBD
(n=5) (C) mice from days 10 and 18 were stained for the presence of Iba-1 in activated
microglia. Representative images of day 18 spinal cords from each group are depicted.
For each mouse two spinal cord sections were selected from the lumbosacral region of
the spinal cord, and the area of each section covered by activated microglia was
quantified as a percentage of the total area of the parenchyma. The two sections were
then combined to get an average percentage for each mouse and statistical analysis
was performed on each group (D).
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3.2
3.2.1

Exploring S. aureus SAgs as immunosuppressive agents
The effects of S. aureus SAgs on murine regulatory cells.
Despite multiple attempts under various conditions, we were unable to induce

FoxP3 in mouse Tregs using the S. aureus SAgs in vitro outlined in Table 3.1. However,
when we measured the effects of the superantigens on MDSCs we found that under
several conditions MDSCs were significantly increased by the SAgs, with granulocytic
MDSCs being the most consistently increased (Table 3.2). Unfortunately, many of the
SAgs varied greatly in their ability to induce this suppressor cell type as well. In later
studies it was determined that despite the lack of FoxP3 induction in T cells, or
consistent induction of MDSCs, splenocytes cultured with S. aureus SAgs were
immunosuppressive through an unknown soluble factor within the supernatants of these
cultures. This work is being continued by others in our lab to determine the
immunosuppressive ability of these supernatants the EAE model.
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Table 3.1
Conditions

Stimulation of Tregs by S. aureus SAgs
Duration SAgs

6 well plate; 10E6 4 Days
cells in 4mls of
media; TGF-β
added at 24hrs
and 72hrs

SEC
(50ng/well)

6 well plate; 10E6 4 Days
cells in 4mls of
media; TGF-β
(20ng/well) and
IL2 (7.5ng/well)
added at 24hrs
and 72hrs
6 well plate; 13E6 4 Days
cells in 4mls of
media; TGF-β
(20ng/well) and
IL2 (20ng/well)
added at 24hrs
and 72hrs

SEC
(50ng/well)

SEC
(50ng/well)

Notes

Effect

Single wells
were done for
each condition.
Statistical
analysis was
not done.
Single wells
were done for
each condition.
Statistical
analysis was
not done.

No increase in Treg
percentages was
seen with the
addition of SEC
Treg percentages
generally appeared
to be lower with the
addition of SEC

FoxP3/GFP
Treg percentages
mice were used appeared to be
for this study.
slightly higher with
Single wells
the addition of SEC;
were done for
however SEC did
each condition. not have much
Statistical
affect when TGF-β
analysis was
and IL2 were added
not done.
6 well plate; 9E6
4 Days
SEC
FoxP3/GFP
Treg percentages
cells in 4mls of
(50ng/well) mice were used appeared to be
media; TGF-β
for this study.
slightly higher with
(20ng/well) and
Single wells
the addition of SEC;
IL2 (20ng/well)
were done for
however SEC did
added at 24hrs
each condition. not have much
and 72hrs
Statistical
affect when TGF-β
analysis was
and IL2 were added
not done. This
was a repeat of
the previous
study.
This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
Tregs with S. aureus superantigens.
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Table 3.1 (continued)

Conditions

Duration SAgs

Notes

Effect
Treg percentages
appeared to be
slightly higher with
the addition of SEC;
and Treg
percentages were
reduced by anti-IL2
and anti-TGF-β
both with and
without SEC
Treg percentages
appeared to be
slightly higher with
the addition of SEC;
and Treg
percentages were
reduced by anti-IL2
and anti-TGF-β
both with and
without SEC

6 well plate; 10E6 4 Days
cells in 4mls of
media; anti-TGFβ (4µg/well) and
anti-IL2
(4µg/well) added
at 24hrs and
72hrs

SEC
(50ng/well)

FoxP3/GFP
mice were used
for this study.
Single wells
were done for
each condition.
Statistical
analysis was
not done.

6 well plate; 10E6 4 Days
cells in 4mls of
media; anti-TGFβ (4µg/well) and
anti-IL2
(4µg/well) added
at 24hrs and
72hrs

SEC
(50ng/well)

6 well plate; 10E6 4 Days
splenocytes in
4mls of media +/2.5E6 purified
dendritic cells

SEC
(50ng/well)

FoxP3/GFP
mice were used
for this study.
Single wells
were done for
each condition.
Statistical
analysis was
not done. This
was a repeat of
the previous
study.
Single wells
were done for
each condition.
Statistical
analysis was
not done.

Adding dendritic
cells did not
enhance the effects
of SEC on Treg
percentages. SEC
had slightly lower
percentages of
Tregs
This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
Tregs with S. aureus superantigens.
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Table 3.1 (continued)

Conditions

Duration SAgs

96 well plate; 2E6 4 Days
splenocytes in
0.2mls of media
+/- 1E6 purified
dendritic cells or
1E6 splenocytes
in 0.2mls of
media + 1E6
purified dendritic
cells
96 well plate; 1E6 5 Days
splenocytes in
0.2mls of media +
1E6 cells bone
marrow cells

6 well plate; 10E6 5 Days
splenocytes or
5E6 splenocytes
+ 5E6 bone
marrow cells in
4mls of media

SEC
(2.5ng/well)

SEC
(5ng/ml),
SEG
(5ng/ml),
SEI
(5ng/ml),
SEM
(5ng/ml),
SEN
(5ng/ml),
SEO
(5ng/ml),
TSST
(5ng/ml),
SEC
(5ng/ml),
TSST
(5ng/ml)

Notes

Effect

FoxP3/GFP
mice were used
for splenocytes,
but WT mice
were used to
obtain dendritic
cells.

SEC significantly
reduced Treg
percentages in 2E6
splenocytes with
1E6 dendritic cells

SEM and SEN
significantly
reduced the
percentage of Tregs

Single wells
were done for
each condition.
Statistical
analysis was
not done.

SEC did not appear
to effect Treg
percentages

This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
Tregs with S. aureus superantigens.
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Table 3.2

Stimulation of MDSCs by S. aureus SAgs

Conditions

Duration

96 well plate;
2E6
splenocytes in
0.2mls of media

1&2
Days

SAgs

Notes

Effects

SEC
Since
Day 1: SEG and
(5ng/ml),
splenocytes
SEM significantly
SEG
were used, very decreased
(5ng/ml),
low numbers of
Granulocytic
SEI
CD11b+ cells
MDSCs
(5ng/ml),
were recovered
SEM
(5ng/ml),
SEN
(5ng/ml),
SEO
(5ng/ml),
TSST
(5ng/ml),
96 well plate;
2&3
SEC
Since
Day 2: SEG and
2E6
Days
(5ng/ml),
splenocytes
SEM significantly
splenocytes in
SEG
were used, very increased the
0.2mls of media
(5ng/ml),
low numbers of
percentage of
+
SEI
CD11b cells
Granulocytic
(5ng/ml),
were recovered. MDSCs
SEM
Day 3: SEG, SEM,
(5ng/ml),
SEN and TSST
SEN
significantly
(5ng/ml),
increased the
SEO
percentage of
(5ng/ml),
Granulocytic
TSST
MDSCS
(5ng/ml),
This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
MDSCs with S. aureus superantigens
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Table 3.2 (continued)

Conditions

Duration

96 well plate;
2E6
splenocytes in
0.2mls of media

3 Day

SAgs

Notes

Effects

SEC
Since
No significance
(5ng/ml),
splenocytes
found
SEG
were used, very
(5ng/ml),
low numbers of
SEI
CD11b+ cells
(5ng/ml),
were recovered.
SEM
(5ng/ml),
SEN
(5ng/ml),
SEO
(5ng/ml),
TSST
(5ng/ml),
96 well plate;
3 Days
SEC
Since
SEG, SEI, SEM,
2E6
(5ng/ml),
splenocytes
SEN, TSST
splenocytes in
SEG
were used, very significantly
0.2mls of media
(5ng/ml),
low numbers of
increased the
SEI
CD11b+ cells
percentage of
(5ng/ml),
were recovered. Monocytic and
SEM
Granulocytic
(5ng/ml),
MDSCs
SEN
(5ng/ml),
SEO
(5ng/ml),
TSST
(5ng/ml),
This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
MDSCs with S. aureus superantigens.
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Table 3.2 (continued)
Conditions

Duration

SAgs

Notes

Effects

96 well plate;
1E6
splenocytes in
0.2mls of media
+/- 1E6 cells
bone marrow
cells

5 Days

SEC
(5ng/ml),
SEG
(5ng/ml),
SEI
(5ng/ml),
SEM
(5ng/ml),
SEN
(5ng/ml),
SEO
(5ng/ml),
TSST
(5ng/ml),
SEC
(5ng/ml),
TSST
(5ng/ml)

Use of bone
marrow greatly
increased the
number of
MDSCs
recovered from
cultures.

SEM, SEN and
TSST significantly
decreased
Monocytic MDSCs,
but SEI, SEM, SEN,
and TSST
significantly
increased the
Granulocytic
MDSCs

6 well plate;
5 Days
10E6
splenocytes or
5E6 splenocytes
+ 5E6 bone
marrow cells in
4mls of media

Single wells
were done for
each condition.
Statistical
analysis was not
done.

Although statistical
analysis was not
done SEC did not
appear to effect
MDSC percentages;
TSST reduced the
percentage of
Granulocytic
MDSCs
This table lists the culture conditions, duration of culture, SAg used, special notes, and
significant effects noted for each condition tested during our experiments on stimulating
MDSCs with S. aureus superantigens.
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3.3
3.3.1

Cnr1-/- vs WT EAE
Clinical scores
By analyzing average AUC for each group of mice we found that Cnr1-/- mice with

EAE (n=12) had significantly higher levels of disease over the 18 day time course as
compared to their WT littermates (n= 14)(Figure 3.11A). Saline treated miceCnr1-/(n=13) and WT (n=13) mice had no clinical disease. Figure 3.11B shows the
progression of clinical disease during the 18 day time course.
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Figure 3.11 Differences in clinical EAE between Cnr1-/- and WT littermates
Clinical scores for WT/SAL (n=13), WT/EAE (n= 14) Cnr1-/-/SAL (n=13) and Cnr1-/-/EAE
(n=12) mice were recorded over the 18 day time course of disease. Average area under
the curve (AUC) was then calculated for each experimental group (A). The clinical
scores were also graphed over time to show clinical progression for each group (B).
Analysis of the average area under the curve for disease progression of each group
showed a statistically significant difference between the Cnr1-/- /EAE mice and WT mice.
* p<0.05
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3.3.2

Histologic scoring
The histologic scores obtained from our new scoring process were totaled and

analyzed for each section of spinal cord, and this analysis revealed that Cnr1-/- mice
with EAE had significantly higher levels of cellular infiltration as compared to their WT
littermates in sections 2-4, while the 1st and 5th spinal cord section showed only a
modest difference between these two groups (Figure 3.12A). No infiltration was seen in
any of the saline mice examined. To verify the validity of this new scoring system, the
correlation between total histologic score and clinical score on day 18 was analyzed
(Figure 3.12B). Total lesion area was also tabulated for each mouse over the 5
sections, and then correlated to the clinical score to determine if lesion area would be a
more representative measurement than our histologic scoring system (Figure 3.12C).
When section scores were totaled for each mouse and compared to clinical score at the
day 18 time point, the histologic scores showed a high level of correlation to clinical
scores (r2 = 0.7171) (Figure 3.12B). A similar level of correlation was found between the
total lesion area and clinical score for each mouse (r2 = 0.7563) (Figure 3.12C).
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Figure 3.12 Histologic scoring
Using the histologic scoring system outlined above, histologic scores for WT/SAL
(n=13), WT/EAE (n= 14) Cnr1-/-/SAL (n=13) and Cnr1-/-/EAE (n=12) mice were obtained
and analyzed by section (A). To validate this method of scoring, the clinical scores were
also correlated to the clinical scores for each mouse (B). Lesion area for each mouse
was also tabulated by finding the lesion area for each of the 5 spinal cord sections and
adding them together, and then this area was correlated to the clinical score for each
mouse to determine if lesion area was more representative of clinical disease (C). *
p<0.05
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3.3.3

ELISAs

MOG35-55 ex vivo restimulation
Analysis of IFN-γ and IL-17A in serum taken on day 18 and supernatants from ex
vivo restimulated splenocytes showed that production of IFN-γ was significantly higher
in restimulated cells from Cnr1-/-/EAE mice as compared to WT/EAE mice (Figure
3.13A). However, no difference was seen with serum IFN-γ, serum IL-17A, or
supernatant IL-17A (Figure 3.13B-D).
Anti-CD3/anti-CD28 and SEM in vitro stimulation
To further investigate the T cell IFN-γ response of the Cnr1-/- mice, naïve
splenocytes were cultured for 2 or 3 days in the presence of anti-CD3/anti-CD28
antibodies or SEM, and IFN-γ was measured in the supernatants of these cultures by
ELISA. For both male and female mice, the IFN-γ response in WT splenocytes
stimulated with anti-CD3/anti-CD8 antibodies was significantly higher than that from
Cnr1-/- mice at two different concentrations. Interestingly, while SEM treated splenocytes
showed a similar trend to the anti-CD3/anti-CD28 treated splenocytes, the differences
observed between WT and Cnr1-/- mice did not reach the same level of significance
seen with anti-CD3/anti-CD28 stimulation (Figure 3.14 A-D).
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Figure 3.13 IFN-γ and IL-17A in serum and MOG35-55 restimulation cultures
Splenocytes were harvested from WT/SAL (n=13), WT/EAE (n= 14) Cnr1-/-/SAL (n=13)
and Cnr1-/-/EAE (n=12) mice and restimulated with MOG35-55 peptide for 3 days. The
supernatants from these cultures were then tested by ELISA for concentrations of IFN-γ
(A) and IL-17A (B). Serum was also taken from each mouse at time of necropsy and
tested by ELISA for concentrations of IFN-γ (C) and IL-17A (D). * p<0.05

71

Figure 3.14 Anti-CD3/anti-CD28 and SEM stimulation of T cells
Splenocytes were harvested from female and male WT and Cnr1-/- mice and stimulated
with either anti-CD3/anti-CD28 antibodies or SEM SAg for 2-3 days before IFN-γ
concentration within the supernatants were analyzed by ELISA (A-D). These
experiments were performed in duplicate for both female and male mice.* p<0.05,
**p<0.01, ***p<0.001, **** p<0.0001
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3.3.4

Flow cytometry

MOG35-55 ex vivo restimulation
Analysis of the percentage of IFN-γ producing cells within the ex vivo
restimulated splenocytes from EAE mice by flow cytometry revealed no significant
differences between the Cnr1-/- mice and WT littermates. However, it did show the
primary source of IFN-γ to be a CD3-CD4-CD8- cell population (Figure 3.15).

Anti-CD3/anti-CD28 and SEM in vitro stimulation
Analysis of the percentage IFN-γ producing cells within the in vitro stimulated
splenocytes by flow cytometry revealed a significantly higher percentage of CD8+IFN-γ+
T cells in the anti-CD3/anti-CD28 stimulated WT cells as compared to the Cnr1-/- cells.
Unlike the ex vivo restimulation, the CD3+ population plays a large role in IFN-γ
production (Figure 3.16).
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Figure 3.15 Analysis of IFN-γ production in MOG35-55 restimulated splenocytes by flow
cytometry
For one round of EAE IFN-γ production was analyzed in the ex vivo MOG35-55
restimulated splenocytes of WT/SAL (n=5), WT/EAE (n= 6) Cnr1-/-/SAL (n=5) and Cnr1-//EAE (n=5) mice by flow cytometry, and IFN-γ producing cells were subdivided based
on their CD4, CD8 and CD3 expression (A). Analysis of various cell types revealed no
significant differences between Cnr1-/- /EAE and WT/EAE mice. A significantly higher
percentage of CD3+CD4+CD8- cells was seen in Cnr1-/- /Saline mice as compared to
WT/Saline mice. Additionally, in these experiments CD3 - cells appear to be the
predominant source of IFN-γ (B). * p<0.05
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Figure 3.16 Analysis of IFN-γ production in anti-CD3/anti-CD28 and SEM stimulated
splenocytes by flow cytometry
IFN-γ production was analyzed in the anti-CD3/anti-CD28 antibody or SEM stimulated
splenocytes from female and male Cnr1-/- and WT mice by flow cytometry, and IFN-γ
producing cells were subdivided based on their CD4, CD8 and CD3 expression (A).
Analysis of various cell types revealed a significantly lower percentage of CD3 +CD4CD8+IFN-γ+ cells in Cnr1-/- as compared to WT mice when splenocytes were stimulated
with anti-CD3/anti-CD28 antibodies. Additionally, in these experiments CD3 + cells
appear to be the predominant source of IFN-γ. The graph in this figure represents one
of the female 3 day stimulations of the in vitro experiments for comparison to the ex vivo
3 day restimulation of the female EAE mice in figure 3.14 (B). * p<0.05, ** p<0.01
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CHAPTER IV
DISCUSSION
The primary treatment for MS revolves around a two-step approach that first
uses immunosuppressive drugs, such as corticosteroids, to reduce the severity of
disease, and then uses immunomodulatory drugs, such as glatiramer acetate and IFNβ, to reduce the occurrence of relapses. While this method does help patients that are in
the relapsing and remitting stage of disease, it does very little to stop the long term
progressive stages of MS [1-3]. For this reason the search for more viable therapies is
still underway, and the main focus of the research done in this dissertation has been
dedicated to exploring potential therapeutics, such as CBD and S. aureus induced
regulatory cells, and potential therapeutic targets, such as the CB1 receptor.
Unfortunately, no conclusive evidence has been collected for the use of SAgs as a
therapeutic agent in MS, and as we previously mentioned we had some difficulty
producing a consistent response from the suppressor cell populations while using
various Sags. Therefore, the main focus of this discussion will revolve around our
experiments with CBD and Cnr1-/- mice in the EAE model.
4.1

CBD in the EAE model
Recently, CBD has shown promise as a treatment for MS through its use in the

EAE model and the use of Sativex in MS patients; however the number of studies
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looking at CBD in the EAE model is limited, and none have examined CBD alone in MS.
One study using the MOG35-55 peptide to induce EAE has shown that when CBD was
administered i.p. for 3 days after the first signs of disease it was capable of reducing
microglial activation and T cell infiltration in the CNS [5]. Similarly, a study looking at the
i.p. administration of CBD in the Theiler’s murine encephalomyelitis virus (TMEV) model
of MS highlighted CBD’s ability to reduce the expression of vascular cell-adhesion
molecule-1 (VCAM-1) on vascular endothelial cells, suppress the production of
chemokines and cytokines, and reduce the activation of microglia [4]. While these
studies provide vital information about the effects of CBD on neuroinflammatory
components of the MS models, they did not evaluate the systemic immune response
associated with the CBD treatment. Furthermore, the i.p. route of administration is used
less often in a clinical setting as compared to oral administration or inhalation.
For these reasons, in our CBD study we sought to examine the response of EAE
to oral CBD by exploring the systemic immune system in addition to the
neuroinflammatory component of the model. By administering CBD for 5 days after the
initiation of disease, we provide evidence that early treatment of EAE with CBD reduced
clinical disease in EAE mice, which was accompanied by a modest reduction in
neuroinflammation. As part of our exploration into the effects of oral CBD on EAE we
chose to examine several suppressor cell types that could potentially contribute to
CBD’s immunosuppressive properties. Tregs and MDSCs represent two distinct linages
of suppressor cells that may have a role in the pathogenesis of MS. Tregs are of
particular interest because several studies have suggested that Treg function is
decreased in MS patients, leading some to speculate that dysregulation of Tregs may
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lead to the CNS based autoimmunity seen in MS [29-31]. On the other hand, MDSCs
have been reported to be increased in the peripheral blood of MS patients and both the
secondary lymphoid tissues and CNS lesions of EAE mice [33, 64, 65].
In previous studies, CBD has been shown to be capable of inducing both Tregs
and MDSCs; however, in our CBD study analysis by flow cytometry showed CBD had
no effect on the percentage of either suppressor cell population in the secondary
lymphoid organs, or on the percentage of Tregs present in the spinal cord. One possible
explanation for the discrepancy between previous MDSC studies and the results
reported here is that the previous studies used i.p. injection for CBD, while we used oral
gavage to administer CBD. This is supported by results from Hegde et al. which suggest
that the induction of MDSCs seen after the i.p. injection of CBD is dependent on the
production of G-CSF by peritoneal mast cells [66]. Additionally, i.p. injection limits CBD
modification by the metabolic enzymes of the liver, which could cause differential effects
as compared to oral administration of CBD. In an earlier paper, Hegde et al. also
showed that i.p. administration of CBD was capable of modest induction of Tregs in
conjunction with increased MDSC in an autoimmune hepatitis model [67]. These results
were more recently supported by our own in vitro study showing CBD’s ability to induce
Tregs at low level T cell stimulation [68]. In the EAE model, i.p. injections of CBD have
been shown to decrease clinical severity, which correlated to an increase number of
MDSCs in the peritoneal cavity. The MDSCs were placed in culture with MOG
restimulated splenocytes or adoptively transferred into EAE mice the MDSCs were
capable of suppressing T cell proliferation and disease respectively [69]. These results
suggest that induction of suppressor cells by CBD may be an important mechanism in
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CBD’s ability to suppress neuroinflammation. However, despite the lack of significant
enhancement of either of the suppressor cell populations in the spleen in the current
study, CBD was still an effective treatment in the EAE model. This suggests that CBD
may have differential effects on the immune response depending on the route of
administration.
In addition to examining the suppressor cell populations, ex vivo restimulation of
cellular isolates from the spleen and lymph nodes of each mouse with MOG35-55 peptide
allowed us to examine the effects of oral CBD on four separate MOG-specific
inflammatory T cell populations at three separate time points: CD4 +IFN-γ+ (Th1 cells),
CD4+IL-17A+ (Th17 cells), CD8+IFN-γ+ (Tc1 cells), and CD8+IL-17A+ (Tc17 cells).
Analysis of these T cell populations by flow cytometry after restimulation revealed a
significant decrease in the percentage of MOG-specific Tc1 cells by CBD in EAE on day
10. This decrease in the percentage of Tc1 cells within the spleen corresponded to a
reduction in clinical disease and neuroinflammation at the day 18 time point. In previous
studies IFN-γ production was shown to be reduced in vitro and in vivo with CBD
treatment, and very recently this relationship has been shown in the CNS of EAE mice
treated with i.p. CBD, although no work was done to identify the source of the IFN-γ
within the CNS [42, 70, 71]. Here we have shown that CBD suppresses the peripheral
Tc1 population and is capable of reducing clinical disease in the EAE model even when
administered before the clinical signs or neuroinflammation are present. This correlation
suggests that CBD could be effective in reducing the pathogenesis of MS, since CD8+ T
cells have been shown to be one of the predominant cell types in the CNS lesions of
MS patients [23]. Furthermore, CD8+ T cells have been shown to be capable of initiating
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EAE, which might explain why inhibition of the Tc1 cells has such a profound effect on
EAE pathogenesis [72].
Interestingly, when ELISAs were performed on the supernatants from the
cultures to determine total cytokine production there was an unexpected spike in IFN-γ
production by CBD in EAE mice on day 18. This increase in IFN-γ production could
represent a delay in the immune response in this group of mice due to the CBD
treatment, and suggests that given enough time these mice would eventually begin to
develop more severe disease; however, further work must be done to determine the
population of cells that are responsible for this increase in IFN-γ production. In our
studies of EAE in Cnr1-/- mice we did find that one of the major contributors to IFN-γ
concentrations in supernatants during ex vivo restimulation was actually a CD3population of cells, and taken together these results suggest that although there was
suppression of the Tc1 cells in this study, IFN-γ production by another cell type might
have been enhanced by CBD. Importantly, in the study by Elliott et al., a method similar
to the one here was used to restimulate splenocytes from EAE mice, and it was
determined that supernatants from splenocyte cultures of CBD treated mice had lower
levels of IFN-γ and IL-17A, and higher levels of IL-10 as compared to EAE mice that did
not receive CBD. Together our results and theirs suggest that duration or route of CBD
administration may affect the long term suppression of the IFN-γ response. Further work
needs to be done to determine exactly which cell types are affected by CBD.
Unlike the effects seen on the Tc1 population, no correlation was seen in the
present study between CBD treatment and IL-17A producing T cells from either
secondary lymphoid tissue, despite previous reports of CBD’s effects on IL-17A
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production [71, 73]. In particular, a study by Kozela et al. showed that in vitro treatment
of T cells with CBD reduced IL-17A production, but did not affect IFN-γ production [73].
The contrast in cytokine production seen between their study and ours might hint at a
temporal component to CBD’s effects, since their study examined the in vitro effects of
CBD only 24 hr after the MOG35-55 specific T cells were stimulated, and our study
examined the in vivo effects of CBD after 48 hr of restimulation. Another explanation for
the lack of effect seen with IFN-γ in the Kozela et al. paper could be that the
concentration of CBD used was not high enough to affect IFN-γ levels. In a study by
Kaplan et al. a range of concentrations were examined, and the results shown by this
study suggest that higher concentrations provide more IFN-γ suppression [42]. Based
on these inconsistencies, it is apparent that more work needs to be done to explore the
temporal and dose dependent effects of CBD on cytokine production, with specific
attention on IL-17 and IFN-γ, so that a more conclusive connection can be made
between CBD and its effects on these two cytokines.
Despite the differences in CBD’s effect on cytokine production between our
studies and others, the reduction by CBD on neuroinflammation and T cells present in
the white matter tracts of the brain and spinal cord of EAE mice was consistent with
other studies. Specifically, our results mirror those seen by Kozela et al. who noted
reduced levels of T cell infiltrates in the spinal cord with i.p. CBD treatment, and
observations seen by Mecha et al. who noted reduced leukocyte infiltrates within the
brain of EAE mice with i.p. CBD treatment [4, 5]. However, in this study the reduction in
neuroinflammation , as measured by histological analysis and flow cytometry at the day
18 time point, did not reach the level of statistical significance expected, suggesting that
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reduced leukocyte infiltration is only one of the neuroprotective mechanisms by which
early CBD treatment reduces clinical disease in EAE.
One neuroinflammatory endpoint which differed in the present study as
compared previous studies was microglial activation. Here we did not find any
significant difference in microglial activation at the day 18 time point when mice were
treated with CBD. Considering the body of evidence which has shown that CBD does
inhibit microglial activation, we believe that there might have been a delay in microglia
activation in the mice treated with CBD; however it likely occurred between day 10 and
day 18, and was undetectable by day 18 [4, 5]. To determine if microglial activation is
indeed delayed by oral CBD in the EAE model, a microglia specific investigation of days
10-18 would need to be conducted. It is also important to note that the functional
capabilities of the cells within the CNS were not examined, so the possibility exists that
the cells present within the CNS of CBD treated mice have more of an
immunosuppressive phenotype which would contribute to the reduced clinical disease
seen in EAE/CBD mice. In consideration of possible functional changes within the T cell
compartment, the number of colocalization events was determined between the CD4+
and CD8+ T cells within each lesion to estimate possible changes in communication
between the two cell types. It was determined that low numbers of colocalization existed
within each lesion with no increases or decreases noted between treatment groups
(results not shown).
When examining the longitudinal sections of brain tissue from day 18 mice the
highest levels of infiltrates were noted in the cerebellum of EAE/CO mice, where the T
cells can be seen evenly and specifically spread throughout the white matter tracts with
82

notable amounts of perivascular cuffing, while the gray matter of the cerebellum
remains relatively untouched. Inflammation was also notably seen in the white matter of
the cerebellum of EAE/CBD mice, but to a lesser extent than in the EAE/CO mice. The
choroid plexus of each mouse was also examined for buildup of inflammatory cells with
CBD treatment that might indicate a reduction in the ability of inflammatory cells to
migrate into the CNS; however, there was no evidence of leukocyte buildup within the
choroid plexus of any group at any time point (results not shown).
In the spinal cord CBD showed a similar effect where meningeal, subpial, and
perivascular infiltrates were increased in the EAE/CO mice, and reduced by
administration of CBD. Notably, the spinal cord sections seen in this study show an
almost complete lack of infiltration in the white matter of the nerve roots even in the
EAE/CO group. This observation was unexpected, since one would presume all
myelinated tracts to be targeted equally when the mouse was inoculated with MOG 35-55
peptide. One possible explanation may be that leukocytes infiltrate primarily in the
perivascular spaces through the glial limitans and not through the CSF, which would
limit their ability to attack the myelin of the nerve roots that run through the
subarachnoid space. This is supported by the two step pathogenesis put forward by
Sallutso et al. in which the initial step of pathogenesis involves the migration of CCR6 + T
cells across the choroid plexus which facilitate the flow of other leukocytes through the
blood brain barrier at various points in the CNS [32]. Another possible explanation for
this observation is that the myelin sheaths in the nerve roots are fundamentally different
from the myelin sheaths of the spinal cord and brain, and do not contain high levels of
MOG. This latter explanation is supported by observations made by Pagany et al. who
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found that although MOG can be expressed by Schwann cells intracellularly in vitro and
MOG mRNA can be identified by PCR analysis of the sciatic nerve, expression of MOG
by Schwann cells could not be detected in vivo using IHC [74]. Either way, this
observation raises some important questions about the pathogenesis of EAE, and
provides insight into how peripheral nerves might be immunologically distinct from the
CNS even before they leave the vertebral column.
4.2

Differential IFN-γ responses in Cnr1-/-and WT mice
The purpose of this study was to examine the role of the CB1 receptor in the EAE

model, with a specific focus on differences in the peripheral immune response between
Cnr1-/- mice and WT littermates. This was done as a continuation of our previous work
with CBD in the EAE model, since there is the potential for CBD to act indirectly through
the CB1 receptor. As we mentioned previously, CBD has very low affinity for the
cannabinoid receptors; however some studies suggest that CBD can increase serum
anandamide (AEA) levels through the inhibition of fatty acid amide hydrolase (FAAH)
and/or fatty acid binding proteins (FABPs), and AEA is an endogenous ligand for the
CB1 and CB2 receptors [75-77].
Our results show that Cnr1-/- C57BL/6 mice have higher levels of clinical disease
as compared to their WT littermates. These results are slightly different than results
previously reported. In one study, the authors found that ABH Cnr1-/- mice had similar
levels of disease onset, incidence and severity, but exhibited less of an ability to recover
from paralytic episodes as compared to WT mice [10]. Then in another study, CB1
deficient mice only showed a higher level of disease when THC was used to treat the
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mice. The assumption in this later study was that the CB1 receptor didn’t play a role in
suppressing disease in the steady state, but was important in cannabinoid therapies [9].
The differences seen between our results and those seen in the ABH mice might be due
to a strain difference in the endocannabinoid system. More specifically, since neither of
the previous studies in ABH mice showed the higher level of disease severity in Cnr1-/mice that we show here and the latter study showed differences in clinical disease only
upon activation of the CB1 receptor with THC, there may be higher levels of
endocannabinoids or higher sensitivity of the CB1 receptor to endocannabinoids in
C57BL/6 mice as compared to ABH mice. A previous study using C57BL/6 mice in the
EAE model also found that mice treated with SR141716, a CB 1 receptor antagonist,
developed EAE more rapidly than vehicle treated mice, which resembles the differences
in early EAE that we found in our studies [78]
To confirm the results of our clinical scoring, a new histologic scoring system was
developed to support the findings and determine which regions within the lumbosacral
spinal cord differed between Cnr1-/- mice and their WT littermates. Differences seen in
sections 2, 3, and 4 are important since these sections represent the lumbosacral
intumescence, the region of the spinal cord where the nerves for the hind limbs branch
off. Higher histologic scores for these sections could reasonably result in an increase in
dysfunction in the hind limbs and worse clinical disease. We also found that our
histologic scoring system was more sensitive for detecting disease than clinical scores.
This is shown in Figure 3B, where some of the mice with a clinical score of 0 received a
histologic score >0. One of the major challenges associated with the EAE model is that
there is no good way to correlate the commonly used clinical scoring systems with
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histologic disease [10, 69, 71]. To help resolve this problem, the new scoring system is
designed to specifically account for the complex distribution of lesions found in the
lumbosacral region of the spinal cords of EAE mice, and simplifies the quantification of
these lesions into a scoring system that can be easily analyzed using a Mann-Whittney
U test or correlated to clinical disease. To validate the scoring system we generated
both a total histologic score and a total lesion area for each spinal cord, and correlated
these to the clinical score for each mouse. Analysis of the lesion area showed only a
slight increase in the r2 value as compared to the histologic scoring system, which
shows that either method would be reasonable for confirming clinical disease. These
results show that our method of histologic scoring is a relatively simple way to validate
clinical scores in EAE mice. Another method commonly used for analyzing
neuroinflammation in the EAE model is by flow cytometry of cells obtained from
homogenizing the spinal cord [79, 80]. While this is an undeniably valid way to analyze
immune infiltrates, our model does have some advantages over this method. One of the
major advantages is that our scoring system allows you to analyze lesion distribution
along the spinal cord, and preserves the tissues for future histologic stains. When flow
cytometry is used to analyze neuroinflammation, the entire spinal cord is used, which
does not show distribution over the spinal cord, and if further information is required, the
entire study must be repeated. It is our hope that this method will provide researchers
who utilize the EAE model with another tool to validate clinical differences seen in the
model, without needing access to anything more than a microscope and the reagents
for an H&E stain. Moreover, the preservation of tissues will allow researchers to revisit
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previous studies with more immunohistochemical technics to collect more data without
the need to perform additional studies.
In addition to our examination of neuroinflammation, we also chose to examine
IFN-γ and IL-17A in the peripheral immune response. These two cytokines are
commonly used endpoints in the EAE model because Th1 cells and Th17 cells have
been shown to be important in the pathogenesis of EAE and MS [20-22, 71, 73, 81].
Analysis of IFN-γ and IL-17A concentrations within the supernatants of MOG 35-55
restimulated splenocytes and serum obtained from our EAE mice showed increased
levels of IFN-γ within the supernatants restimulated splenocytes from Cnr1-/- mice as
compared to their WT littermates. These finding suggest that the antigen specific IFN-γ
response to MOG35-55 is much higher in Cnr1-/-/EAE mice as compared to WT/EAE mice.
These results are also consistent with those found in another study which showed that
treatment of EAE mice with SR141716A, a CB1 receptor antagonist, increased IFN-γ
production in MOG35-55 restimulated splenocytes, along with other proinflammatory
cytokines such as IL-17A, IL-1β, IL-6, and TNF-α [82].
Since the restimulation method used in these EAE studies relies on the uptake of
MOG35-55 by APCs and presentation to T cells, we decided to further test the T cell
specific IFN-γ responses of Cnr1-/- and WT mice using two additional methods of T cell
stimulation: anti-CD3/anti-CD28 and the S. aureus superantigen SEM. Anti-CD3/antiCD28 antibodies act directly on the T cell receptor (TCR) CD3 subunit and on the CD28
co-stimulatory molecule to invoke a strong T cell specific response, which includes
increases in IFN-γ production. Conversely, the stimulation of T cells with SEM, a
pyrogenic toxin superantigen, is dependent on cross bridging of the TCR to MHC class
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II molecules on APC [83]. Thus by including both methods we were first able to assess
the ability of T cells alone to produce IFN-γ and then assess their ability to produce IFNγ in an APC dependent manner. Interestingly, when anti-CD3/anti-CD28 antibodies
were used a very robust IFN-γ response was seen in WT and Cnr1-/- mice, but the WT
mice had nearly a two-fold higher level of IFN-γ in the supernatants as compared to the
Cnr1-/- mice. In contrast to this, when SEM was used to stimulate the splenocytes a
lower level of IFN-γ was observed as compared to the anti-CD3/anti-CD28 stimulation
and although WT mice generally had higher levels of IFN-γ production compared the
CB1 deficient mice the difference was less significant than observed with anti-CD3/antiCD28 stimulation. Since these results contradicted the results found from the ex vivo
restimulation of splenocytes in our EAE studies, we used flow cytometry to determine
the sources of IFN-γ under both conditions.
Interestingly, while the results from our flow cytometry did not show a difference
in the percentage of IFN-γ producing cells between Cnr1-/- and WT mice under most
conditions, with the one exception being the anti-CD3/anti-CD28 stimulated CD3+CD8+
cells, it did reveal that the major source of the IFN-γ in our EAE studies was a CD3-CD4CD8- cell population and the major source of IFN-γ from the T cell specific stimulations
were the CD3+CD4+ and CD3+CD8+ populations. Based on these results it is clear that
IFN-γ production in the EAE model was enhanced in the peripheral immune system of
Cnr1-/- mice as compared to WT mice, however the increased IFN-γ production ex vivo
is not explained by an increase in IFN-γ production by T cells specifically. Furthermore,
since our flow cytometry analysis showed this cell population to be a CD3 - population,
we can rule out NKT cells and γδ T cells as the source of IFN-γ. These results suggest
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that NK cells or APCs could be sources of IFN-γ since they are both CD3-. Given the
fact that only MOG35-55 peptide was added to the cultures to stimulate an antigenspecific response, the data suggest the major source of IFN-γ in the ex vivo cultures
was likely either macrophages or dendritic cells, which would suggest the inflammatory
potential of these APCs are enhanced in the Cnr1-/- mice. This is supported by another
study by Lou et al. in which they examined the effects of SR141716A on IFN-γ
production in T cells from EAE mice and BV-2 microglia. When this group examined the
effects of SR141716A on T cells from EAE mice they did so by flow cytometry, much
like our present study, and while they did find a significant increase in the overall
percentage of CD4+IFN-γ+ cells with SR141716A treatment, the total percentage of
CD4+IFN-γ+ cells was less than 5% with the difference found between groups only being
about 1% of cells [78]. These numbers are very similar to those found in the present
study for percentages CD4+IFN-γ+ cells, despite the fact that they specifically isolated
CD4+ T cells and co-cultured them with BV2 microglial cells prior to flow cytometry.
Additionally, when this group examined IFN-γ production by BV2 microglial cells by
ELISA of supernatants from culture, they found that SR141716A treated cells had
significantly more IFN-γ production as compared to those not treated with
SR141716A[78]. While further studies need to be done to confirm the source of IFN-γ in
our study, the similarities between microglial cells and macrophages strongly support
macrophages as major source of IFN-γ within the peripheral immune response of the
EAE model and that CB1-deficient mice may have a higher level of IFN-γ production in
these cells. It should also be noted that when mononuclear cells (MNC) from the spleen
of EAE mice in the presence of MOG35-55 and MBP68-86 in their study, an increase in
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IFN-γ production was also noted in Lou et al. however in the previous study no
determination of cell types was made for this analysis [78]
4.3

Conclusions
The exploration of CBD as an immunosuppressive therapy has shown promise in

models of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and MS [3-5],
and the neuroprotective effects of the CB1 receptor have been highlighted in other
studies [9, 10]. However, in the studies outlined in this dissertation we sought to further
the understanding of how the CB1 receptor and CBD modulate the peripheral and
subsequent neuroimmune response in the EAE model. The major contributions from
these studies are as follows. 1) Our early studies with CBD in the EAE model
determined that early treatment with oral CBD significantly decreased the Tc1
responses in the spleen of CBD-treated EAE mice on day 10, which correlated with
modest reduction in neuroinflammation of the CBD-treated EAE mice on day 18. These
data are significant since suppression of immune function endpoints were observed
following oral CBD and the reduction of clinical and neurological disease seen at later
time points after early treatment with CBD suggest that residual effects of CBD
treatment were still present for over a week after discontinuing the treatment. 2) Our
examination of IFN-γ production in Cnr1-/- and WT mice under various experimental
conditions found that CB1-deficient mice had both increased and decreased production
of IFN-γ which was highly dependent on which cells were stimulated. More specifically,
when T cells dominated IFN-γ production WT mice had higher levels of IFN-γ, and when
the CD3- populations dominated IFN-γ production Cnr1-/- mice had higher levels of IFNγ. These results represent an important step in understanding the complex mechanism
90

of the CB1 receptor in different cells types, and under different stimulation conditions.
Moreover, with the recent increase in the clinical application of cannabinoids for various
diseases, including MS, these results represent a vital piece of information that may
guide future clinical decisions, since they imply that inhibition of the CB 1 receptors may
enhance the inflammatory responses of innate cells and depress the inflammatory
response of T cells, and that the reverse may be true for stimulation of the CB 1
receptors. 3) A new method of scoring histologic disease was developed in our later
studies which we hope will help standardize the methods for reporting histologic disease
in future studies. In the author’s opinion, this is a much needed addition to the use of
EAE as a model for MS, which will not only help to confirm clinical scores obtained while
using these studies, but also deepen our understanding of the pathogenesis of this
complex disease.
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CHAPTER V
THE EAE MODEL: ISOFLURANE AND PASSIVE EAE

Pertussis Toxin (PTX) is often used by other labs to enhance the severity of the
EAE model; however PTX is also an inhibitor of G-protein coupled receptors like CB1
and CB2 [84]. Since the CB1 receptors were considered to be important factors in our
Cnr1-/- study, and indirectly in our CBD study through CBD’s ability to modulate AEA
metabolism, we decided to avoid the possible confounding factor of inhibiting these
receptors with PTX. As a result we saw a milder form of EAE than what is reported by
other labs, which made analysis of clinical disease more difficult [69, 85, 86]. Thus, in
addition to the work outlined in the chapters above, we have also been exploring other
methods of enhancing clinical disease that do not require PTX. This chapter will outline
two such methods, and discuss the outcome from each method.
5.1

Effects of isoflurane on the EAE model
In our EAE model we often find increases in the peripheral immune response to

MOG35-55 peptide even when no clinical disease is present. Based on this, we believe
that one of the major obstacles for our model is centered on the infiltration of the
MOG35-55 specific immune cells across the BBB, and thus we began looking for ways to
enhance migration of cells across the BBB. The method outlined in this section was
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developed based a paper which showed that high levels of isoflurane administered to
cats was capable of increasing the permeability of the BBB [87]. Given this evidence we
hypothesized that isoflurane could open the BBB in mice in a similar fashion to that
seen in cats, and that if isoflurane were given to EAE mice in sufficient dosages at the
proper time, it could be used to synchronize the infiltration of immune cells across the
BBB.
5.1.1
5.1.1.1

Methods
Exposure to high levels of isoflurane
Experiments were approved by Mississippi State University Institutional Animal

Care and Use Committee (IACUC). WT female C57BL/6 mice raised at Mississippi
State College of Veterinary Medicine were used for these experiments. Prior to
prolonged exposure to isoflurane, mice were briefly anesthetized using isoflurane and
injected i.p. with Evans blue dye. 2 hr after injection, mice were placed in a clear plastic
container and exposed to either 3% isoflurane or oxygen for 15mins. Body temperature
was controlled using a heating pad under the plastic container, and mice were
monitored during recovery to be sure there were no complications. The mice were then
euthanized and the spinal cords were placed in 10% NBF for approximately 1 week.
5.1.1.2

Spinal cord processing
Fixation of the spinal column prior to removal of the spinal cord allowed us to

remove the spinal cords without accidental disruption of the blood vessels, which would
have generated a false positive in our images. After fixation, the spinal cords were
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removed from the spinal columns by removing the dorsal lamina of each vertebra and
carefully extracting the length of the spinal cord. The spinal cords were then placed in
OTC and 30µm sections were cut using a cryostat. Evans blue was detected within the
vessels of each section using a fluorescence microscope with a TRITC filter.
Microscopic images were captured using a Lumenera Digital Camera and Infinity
Analyze Software.
5.1.1.3

EAE induction and isoflurane exposure
EAE was induced and scored as described in Chapter 2 using 100 µl of CFA

containing 100 µg of MOG35-55 peptide with 0.5 mg of HKMT. 11 days after EAE
induction mice were exposed to 3% isoflurane or oxygen for 15 minutes as described in
the previous section. Clinical disease was allowed to progress normally until day 18
when the mice were euthanized.
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5.1.2

Results

5.1.2.1

Examination of spinal cords after exposure to isoflurane.

Upon examination of spinal cords from mice exposed to 3% isoflurane and oxygen for
15 mins, we found no evidence extravasation of Evans blue dye in either set of mice
(Figure 5.1)

Figure 5.1

Examination of BBB integrity after exposure to isoflurane

No extravasation of Evans blue dye was noted in mice exposed to isoflurane or oxygen
for 15 mins. The images in the figure are representative images of spinal cords taken at
100 x magnification for isoflurane (A) or oxygen (B) treated mice, and 200 x
magnification images of isoflurane (C) or oxygen (D) treated mice.
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Effects of isoflurane on EAE

5.1.2.2

Exposure to 3% isoflurane for 15mins did not enhance EAE disease progression,
nor did it synchronize initiation of disease as expected (Figure5.2).

Figure 5.2

Clinical EAE after exposure to isoflurane

Clinical progression was monitored over an 18 day time period and mice were exposed
to either 3% isoflurane or oxygen for 15 mins on day 11. No significant difference was
seen between these two groups.

5.1.3

Discussion
In this set experiments we sought to use isoflurane as a method of increasing the

BBB permeability in EAE model. However, we were unable to achieve an increase in
disease incidence or severity by administering isoflurane to EAE mice 11 days after the
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induction of disease. Furthermore, we were unable to show increases in BBB
permeability with isoflurane treatment. This was surprising considering that Tetrault et
al. reported increases in BBB permeability in the cortex and thalamus of cats at 3%
isoflurane, and permeability in the thalamus of cats at 1% isoflurane [87]. In our
experiments, mice exposed to 3% isoflurane did not show any increases in Evans blue
extravasation in the spinal cord as compared to mice treated with oxygen. One possible
explanation for the difference found in our study as compared to theirs is that we are
using mice instead of cats. However it is unlikely that higher levels of isoflurane would
be needed in mice as compared to cats. This is because the Minimum Alveolar
Concentration (MAC), which is the concentration at 1 atmosphere that produces
immobility in 50% of animals exposed to a noxious stimulus, is 1.63±0.06 in cats and
1.41±0.03 in mice [88]. This means that mice are actually anesthetized at slightly lower
concentration than cats on average, and thus the effects of the anesthetic on the BBB
should be similar if not a little more pronounced in mice given the same concentration of
isoflurane. Additionally, since less than 0.2% of the inspired dose of isoflurane is
metabolized by the animal, it is unlikely that the higher metabolism of mice would have
any significant impact on blood concentrations of isoflurane [88].
In addition to examining BBB permeability with Evans blue dye, we also decided
to try to enhance our EAE model with isoflurane. For this experiment, day 11 was
chosen for the administration of isoflurane based on increases in peripheral immune
responses seen in our previous studies. For example, in our EAE/CBD study we clearly
saw an increase in the MOG specific IFN-γ responses at day 10. Thus, we
hypothesized that by day 11 a population of MOG specific T cells should be present and
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able to cross the BBB if it was sufficiently disrupted. The results from this experiment
seem to reinforce the results found in the previous experiment using Evans blue dye, in
that we saw no change in disease, which suggests that the BBB was not disrupted. The
combined results from these two experiments suggest that isoflurane does not cause
sufficient disruption of the BBB to enhance the EAE model. However, it should be noted
that to fully explore isoflurane as a method of enhancing this model, more time points
for isoflurane administration should be added to future studies.
5.2

Passive transfer model development
In addition to our attempts to increase BBB permeability with isoflurane, our lab

has recently been exploring the use of the P-EAE model as a method of examining the
later stages of the MOG35-55 specific immune response, and as a more robust form of
disease. This model is a useful tool for exploring immune responses of EAE mice
independently from the non-specific responses to CFA and HKMT that are present in
the active EAE model that has been used in our previous studies. In our initial work with
CBD in the active EAE model, we found that CBD was capable of reducing clinical
disease and modestly reducing neuroinflammation, which is similar to results found by
other labs [4, 5]. Thus we hypothesized that CBD would have similar effects on the PEAE model. Here we will discuss a couple of experiments in which we utilized 2D2
transgenic mice to initiate P-EAE, and how the development of this model has led to
some important age dependent discoveries. More specifically, in some of our early CBD
studies with this model we observed that older mice initiated EAE more effectively than
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younger mice, which led us to wonder if there were differences in the cell populations
obtained from older mice as compared to younger mice.
Based on previous studies from other labs, we chose to examine several cell
populations including central memory T cells, effector memory T cells, Th1 cells, Th17
cells, and CD4-CD8- T cells (double negative T cells). The choice to include memory T
cells, Th1, and Th17 cells was inspired by a study that examined the ability of memory T
cells and naïve T cells from 2D2 mice to induce disease in WT mice [89]. Based on this
study we hypothesized that older mice have more robust memory T cell responses as
compared to younger mice, and thus generate higher clinical disease. We also decided
to look for changes in the double negative T cells recovered from 2D2 mice, since a
previous study by Grishkan et al. found that repeated stimulations of T helper cells by
anti-CD3/anti-CD28 coated Dynal beads to simulate the chronic stimulation generated a
double negative population of T cells similar to those found in autoimmune
lymphoproliferative syndrome (ALPS) and systemic lupus erythematosus (SLE) [90]. In
the context of the present study, we examined transgenic T cells for any shift in the
double negative population to see if a similar type of chronic stimulation was occurring
in the transgenic T cells of older mice 2D2 mice.
5.2.1
5.2.1.1

Materials and Methods
P-EAE induction
Experiments were approved by Mississippi State University Institutional Animal

Care and Use Committee (IACUC). Active EAE was induced in 2D2 transgenic C57BL/6
female mice as described in Chapter 2 using 100 µl of CFA containing 100 µg of
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MOG35-55 peptide with 0.5 mg of HKMT. These mice were obtained from Jackson
Laboratories at 8 weeks of age, and were either rested for two weeks before EAE
induction or kept until approximately 6 months of age before active EAE induction. Cells
were then harvested from the spleen, axial lymph nodes, and inguinal lymph nodes for
culture. 20 x106 cells from lymph nodes and spleens were cultured separately in 4mls of
1x RPMI/5%BCS/1% Pen-Strep/50 µM 2-ME for 72 hr in a 6 well plate in the presence
of 50µg/ml of MOG35-55 peptide. All of the cells were then harvested, combined into a
single suspension, and concentrated in PBS so that each WT recipient mouse was
injected i.p. with approximately 30-40 x 106 cells in 200µl of PBS. In later experiments
cells were set aside before culture to stain for central memory and effector memory T
cells, and cells were set aside after culture to stain for central memory T cells, effector
memory T cells, CD3+CD4-CD8- T cells, IFN-γ producing T cells, and IL-17A producing
T cells. After P-EAE induction, the mice were monitored over the next 15 days for
clinical disease using the same scoring system outlined in Chapter 2.
Two sets of experiments were performed using this method of P-EAE induction.
The aim of the first set of experiments was to determine the effects of prolonged CBD
treatment on P-EAE. To this end, P-EAE mice were treated with either 75mg/kg of CBD
in 100µl of CO, 150mg/kg of CBD in 100µl of CO, or 100µl of CO for the entire 15 day
time course of P-EAE. Due to some inconsistencies that were discovered during these
experiments a second set of experiments was then designed to test the age dependent
immune response of 2D2 transgenic mice, and no CBD was used during this set of
experiments.
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5.2.1.2

Staining for flow cytometry
Before culture, cells from the lymph nodes and spleen of each mouse were

stained for central and effector memory T cells, and after the 72hr restimulation culture
with MOG35-55 the cells were stained for central and effector memory T cells, CD3+CD4CD8- T cells, and IFN-γ/IL-17A producing T cells. For the IFN-γ and IL-17A staining cells
were treated with Brefeldin A for 4 hr before extracellular staining. Extracellular staining
was performed in a similar fashion to that described in Chapter 2. Briefly, the cells were
rinsed twice with 1x PBS and stained with 0.1µl of NIR FVD in 50µl of PBS for 30mins
at 4°C. The cells were then rinsed twice more with PBS, and incubated at RT for 15 min
in 50 µl of FC buffer containing 0.5 µl of Fc Block. 50 µl of FC buffer containing 0.3 µl
extracellular antibodies was added to each well and allowed to incubate at RT for 30
min. To stain for central/effector memory T cells, extracellular antibodies included CD3Pacific Blue (BioLegend Clone 17A2), CD4-APC (BioLegend Clone GK1.5) CD8-PECy7 (BioLegend Clone 53-6.7), CD62L-PE-Cy5 (eBioscience Clone MEL-14), CD44BV785 (BioLegend Clone IM7), Vβ11-PE (BioLegend Clone RR3-15), and Vα3.2-FITC
(BioLegend Clone RR3-16). Extracellular antibodies for the CD3+CD4-CD8- T cell stain
included CD3-Pacific Blue (BioLegend Clone 17A2), CD4-APC (BioLegend Clone
GK1.5) CD8-PE-Cy7 (BioLegend Clone 53-6.7), Vβ11-PE (BioLegend Clone RR3-15),
NK1.1-PerCP/CY5.5 (BioLegend Clone PK136), γδTCR-FITC (BioLegend Clone GL3)
and B220-BV785 (BioLegend Clone RA3-6B2). Extracellular antibodies for the IFN-γ
and IL-17A stain included CD3-Pacific Blue (BioLegend Clone 17A2), CD4-APC
(BioLegend Clone GK1.5) CD8-PE-Cy7 (BioLegend Clone 53-6.7), and Vα3.2-FITC
(BioLegend Clone RR3-16). After extracellular staining cells that underwent the memory
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T cell stain and CD3+CD4-CD8- T cell stain were then rinsed twice with FC buffer, fixed
for 15 mins with BD Cytofix, and resuspended in 300µl of FC buffer for flow cytometry.
Cells for the IFN-γ and IL-17A stain were rinsed twice FC buffer, fixed with BD Cytofix
for 15mins, and rinsed once with FC buffer and once with BD Permwash buffer (BD
Bioscience).Then the cells were resuspended in BD Permwash buffer containing 0.5 µl
of IFN-γ-PE (BioLegend Clone XMG1.2) and 0.5 µl of IL-17A-BV650 (BioLegend Clone
TC11-18H10) and allowed to incubate overnight at 4°C. The cells were rinsed with FC
buffer and resuspended in 300 µl of FC buffer for flow cytometry.
Flow cytometry

5.2.1.3

Cells stained with intracellular and extracellular florescent antibodies were
analyzed using an ACEA Novocyte flow cytometer (ACEA Biosciences, San Diego, CA).
5.2.1.3.1

Memory T cells

Live lymphocytes from the MOG35-55 restimulated cells were selected by gating
on cells that did not stain with NIR FVD and then passing them through singlet gate and
a lymphocyte gate based on their SCC and FSC characteristics. Transgenic T cells
were then selected based on their expression of CD3 Vβ11 and Vα3.2. Cells from this
population were then divided based on their expression of CD62L and CD44. Naïve
cells, central memory cells, and effector memory cells were identified as CD62L+CD44-,
CD62L+CD44+, and CD62L-CD44+ respectively (Figure 5.3) as previously described by
Williams et al. [89].
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Figure 5.3

Memory and effector transgenic T cells gating strategy

Cells were first passed through a live cell gate based on NIR FVD staining and then
through a doublet exclusion gate and a lymphocyte gate. From this population
Transgenic T cells were identified as CD3+Vβ11+Vα3.2+ cells, which were then further
divided into naïve, memory, and effector cells based on expression of CD44 and
CD62L. Memory cells were identified as CD44+CD62L+, naïve cells were identified as
CD44-CD62L+, and effector cells were identified as CD44+CD62L-.

5.2.1.3.2

Double negative T cells

Similar to the gating for memory T cells, we first identified live lymphocytes from
the MOG35-55 restimulated cells based on staining with NIR FVD and their SSC and FSC
characteristics. Then, we identified transgenic T cells base on their expression of CD3
and Vβ11. Vα3.2 was excluded from this analysis because we determined in the
memory cell stains that Vβ11 and Vα3.2 are almost exclusively expressed together.
Thus we were able to stain for more markers by excluding Vα3.2 here. Once we
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isolated the transgenic cell population we identified the CD4/CD8 double negative
population as the CD4- CD8- γδTCR- NK1.1- B220- population (Figure 5.4).

Figure 5.4

Double negative transgenic T cells gating strategy

Cells were first passed through a live cell gate based on NIR FVD staining and then
through a doublet exclusion gate and a lymphocyte gate. From this population
Transgenic T cells were identified as CD3+Vβ11+ cells. Double negative cells were then
identified CD4-CD8- cells that were also NK1.1-γδTCR-B220-.

5.2.1.3.3

IL-17A and IFN-γ producing T cells

Lymphocytes were selected as before, and this time expression of CD3 and
Vα3.2 was used to identify transgenic T cells. From this population, we then identified
the CD4+ cells that expressed IFN-γ and IL-17A (Figure 5.5).
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Figure 5.5

Th1 and Th17 transgenic T cells gating strategy

Cells were first passed through a live cell gate based on NIR FVD staining and then
through a doublet exclusion gate and a lymphocyte gate. From this population
Transgenic T cells were identified as CD3+Vα3.2+ cells. This population was then further
divided into CD4+IFN-γ+ cells and CD4+IL-17A+ cells which represented the Th1 and
Th17 populations respectively.

5.2.1.3.4

B cells

For identification of B cells, we used the sample of cells that were stained for
examination of double negative T cells. However, instead of using the other markers
used to identify T cells, we simply changed the analysis to look for cells within the
lymphocyte population that expressed B220 (Figure 5.6)
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Figure 5.6

B cell gating strategy

Cells were first passed through a live cell gate based on NIR FVD staining and then
through a doublet exclusion gate and a lymphocyte gate. From this population B cells
were identified as cells that expressed B220.

5.2.1.4

Histologic staining
Spinal cords were taken for each set of experiments that were performed and

decalcified and placed in paraffin blocks as described in Chapter 2. 5µm sections from
the P-EAE CBD studies were then cut to perform H&E and Iba-1 staining. Sections for
the Iba-1 staining were first deparafinized and rehydrated by placing them through
xylene, 100% ethanol, 95% ethanol, DI water at 2 mins each. Antigen retrieval was
performed by placing the slides in TRS for 30mins in a steamer. The slides were then
allowed to cool for 10mins and rinsed in PBS. Non-specific binding was blocked by
placing the sections in PBS containing 1% BSA and 4% goat serum for 1hr at RT. The
blocking solution was then removed and polyclonal rabbit Iba-1 antibodies were placed
on the sections in PBS/1% BSA/0.1% Tx. The slides were placed at 4°C and allowed to
incubate overnight. The next day the slides were rinsed in distilled water to remove
excess antibodies, and incubated for 2 hr in PBS/1% BSA/0.1% Tx containing Alexa
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Fluor 488 conjugated goat anti-rabbit IgG antibody (1:200). Slides were rinsed and
coverslipped with Vectashield. Images were captured using a Lumenera Digital Camera
equipped with Infinity Analyze Software.
5.2.1.5

Statistical analysis
Statistical analysis performed on clinical scores utilized the Mann-Whitney U test,

while statistical analysis performed on flow cytometry results was done using one-way
ANOVA after transformation of the raw percentages. All statistical analysis was
performed with GraphPad Prism 6 or GraphPad Prism 7 software.
5.2.2
5.2.2.1

Results
Effects of CBD on the P-EAE clinical scores
In our initial examination of the P-EAE model, 6 month old 2D2 mice were used

in two studies to induce P-EAE, and young mice of approximately 10 weeks of age were
used in one final study using CBD. In the first two studies the incidence for P-EAE was
100% in both the P-EAE/CO group and P-EAE/CBD group, and CBD had no effect on
P-EAE (Figure 5.7A). Conversely, when P-EAE was induced using young 2D2 mice with
the same protocol, no clinical disease was found in any treatment group (Figure 5.7B)
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Figure 5.7

Clinical scores for P-EAE CBD studies

P-EAE was induced in WT C57BL/6 mice using restimulated cells from 6 month old 2D2
mice, and recipient mice were treated with either 75mg/kg of CBD in CO or treated with
CO. No difference was seen between the clinical scores of the P-EAE/CBD group and
the P-EAE/CO group (A). The experiment was repeated again with 10 week old 2D2
mice and treatments of 150mg/kg of CBD in CO, 75mg/kg of CBD in CO, or CO were
given to the recipient mice. No clinical disease was seen in any group (B).
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5.2.2.2

H&E and Iba-1
Iba-1 and H&E stains were performed on mice from the first two studies exploring

CBD’s effects on the P-EAE model to examine microglial activation and cellular
infiltration respectively. Examination of histologic stains revealed no difference between
the P-EAE/CO and P-EAE/CBD groups with regards to cellular infiltration or microglial
activation (Figure 5.8).
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Figure 5.8

H&E and Iba-1 staining of mice from P-EAE CBD studies

H&E stains from the two studies in which clinical disease was not abrogated by CBD
showed that there were similar levels of cellular infiltration in CO and CBD treated mice,
and Iba-1 staining revealed similar levels of microglial/macrophage activity within the
spinal cords of CO and CBD treated mice.

5.2.2.3

Induction of P-EAE using old and young mice
Based on the discrepancy seen between P-EAE induced with mice that were 6

months of age vs 10 weeks of age in our initial studies examining the effects of CBD on
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P-EAE, we conducted a set of experiments to determine whether older 2D2 mice were
more capable of inducing clinical disease in the P-EAE model. Clinical scores from
these studies show that by 15 days after the induction of P-EAE, older 2D2 transgenic
mice were able to confer a higher level of clinical disease as compared to younger 2D2
transgenic mice, which confirms our previous observations from the P-EAE CBD study.

Figure 5.9

Clinical scores from P-EAE old vs young studies

P-EAE was induced in WT C57BL/6 mice using restimulated cells from mice 6 months
and 10 weeks of age. Clinical disease began around day 12 for both sets of mice, and
by day 15 the P-EAE mice which were induced using cells from older mice (n=13) had
a significantly higher average clinical score as compared to P-EAE mice which were
induced using younger mice (n=13). * p < 0.05
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5.2.2.4

Memory cells and effector cells
Analysis of memory and effector T cell populations was performed on both

spleen and lymph node isolates before and after the 72 hr restimulation with MOG35-55
peptide. This analysis revealed a significantly higher number of MOG 35-55 specific
transgenic central memory T cells before culture in the spleens of young mice as
compared to those of older mice (Figure 5.10A). Conversely, the lymph nodes and
spleens of 6 month old mice had much higher percentages of MOG 35-55 specific
transgenic effector memory T cells before culture as compared to younger mice (Figure
5.10C). However, after these cells were cultured for 72 hr in the presence of MOG35-55
peptide, the differences in effector and central memory T cells were eliminated (Figure
5.10 B&D). When we analyzed the percentage of transgenic T cells in the secondary
lymphoid organs we found that younger mice had much higher percentages of the
transgenic T cells as compare to older mice, but this difference was lessened after
culture as well (Figure 5.10 E&F). The number of transgenic central memory and
effector memory T cells is represented as percentages of total transgenic T cells,
whereas transgenic T cells are represented as a percentage of the total lymphocytes.
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Figure 5.10 Transgenic memory T cells before and after culture
EAE was induced in 2D2 mice 6 months and 10 weeks of age. 11 days after induction,
single cell isolates were obtained from the spleens and lymph nodes of these mice, and
analyzed before and after restimulation for percentages of transgenic central memory T
cells (A & B), transgenic effector memory T cells (C & D), and total percentage of
transgenic T cells (E & F) using flow cytometry. The number of transgenic central
memory T cells and effector memory T cells are represented as percentages of total
transgenic T cells, whereas the number of transgenic T cells is represented as a
percentage of the total lymphocytes. For central and effector memory T cells, (n=5) for 6
month old mice before and after culture. For central and effector memory T cells in 10
week old mice, (n=3) before culture and (n=6) after culture. For total transgenic T cells,
(n=6) for 10 week old mice before and after culture, and (n=5) for 6 month old mice
before and after culture. * p<0.05, **p<0.01.
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5.2.2.5

CD4-CD8- double negative and B cell populations after culture
Double negative T cells were defined as CD3+CD4-CD8- cells that were also

NK1.1-, γδ TCR-, and B220-. Based on these parameters we were not able to detect any
significant differences between mice that were 6 months and 10 weeks of age in the
double negative T cell populations measured after 72 hr of culture with MOG35-55 peptide
(Figure 5.11A). Since this stain required that we stain for the B cell marker B220, we
also analyzed the percentage B cells that were present after restimulation and it was
determined that there was a modestly higher number of B cells in the cultures from
older 2D2 mice as compared to the 10 week old 2D2 mice (Figure 5.11B). The number
of transgenic double negative T cells is represented as a percentage of total transgenic
T cells, whereas the number of B cells is represented as a percentage of total
lymphocytes.

Figure 5.11 Double negative transgenic T cells and B cells after culture
EAE was induced in 2D2 mice 6 months (n=5) and 10 weeks (n=6) of age. 11 days after
induction, single cell isolates were obtained from the spleens and lymph nodes of these
mice, and analyzed after restimulation for percentages of transgenic CD4 -CD8- T cells
(A) and B cells (B) using flow cytometry. The number of double negative transgenic T
cells is represented as a percentage of total transgenic T cells, whereas the number of
B cells is represented as a percentage of total lymphocytes.
114

5.2.2.6

IFN-γ and IL-17A production in T cells after culture
Upon analysis of cells from the ex vivo restimulated cultures for IFN-γ production,

it was determined that the percentage of transgenic Th1 cells present in these cultures
was significantly higher in the splenocytes of older mice as compared to that of younger
mice. Conversely when cells were analyzed for IL-17A production, we found that the
percentage of Th17 cells present in the restimulated lymph node and spleen isolates
were significantly higher in cells restimulated from young mice as compared to older
mice, although the percentage of cells represented by the Th17 population was less
than 1% of all transgenic T helper cells. The number of Th1 and Th17 cell are
represented as the percentage of transgenic CD4+ cells which express either IFN-γ or
IL-17A respectively.

Figure 5.12 Transgenic Th1 and Th17 cells after culture
EAE was induced in 2D2 mice 6 months (n=5) and 10 weeks (n=6) of age. 11 days after
induction, single cell isolates were obtained from the spleens and lymph nodes of these
mice, and analyzed after restimulation for percentages of transgenic Th1 cells (A) and
transgenic Th17 cells (B). The number of Th1 and Th17 cell are represented as the
percentage of Transgenic CD4+ cells which express either IFN-γ or IL-17A respectively.
* p<0.05, **p<0.01, ***p<0.01, ****p<0.01
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5.2.3

Discussion
The goal of our initial study utilizing the P-EAE model was to explore the effects

of CBD on neuroinflammation during the later stages of the T cell response. However,
we were surprised to find that in contrast to our work with CBD in the active EAE model
CBD did not reduce clinical disease or neuroinflammation in the P-EAE model despite
dosing the mice for the entire 15 day time course of the study. One explanation for this
difference might be due to robustness of disease seen in the P-EAE. In the two studies
in which we were able to induced P-EAE we observed higher clinical scores and more
consistent clinical progression as compared to our active EAE model, and so we must
consider the possibility that CBD is not able to reduce neuroinflammation past a certain
threshold of disease. Another possible explanation for the differences seen between our
two models is that there is a fundamental difference between the cell types involved,
and CBD’s reduced effectiveness in the P-EAE model may be due to certain cell types
playing a lesser role in disease. More specifically, in the P-EAE model the primary
source of inflammation is a memory response from the cells that were injected into the
WT mice, and one of the major cell types that are responsible for this are the 2D2
transgenic T cells. This is in contrast to active EAE, which is driven by HKMT and CFA,
and causes a massive innate immune response. These differences in type of immune
response may play a key role in determining CBD’s effectiveness in reducing
neuroinflammation in EAE. This is similar to the work done by our lab in Cnr1-/- mice
which showed differential IFN-γ production in splenocytes depending on which cell
populations were activated. Like in the previous study, if CBD is capable of reducing
inflammation when the response is predominated by the innate immune response, but
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has no effect on T cells, or more specifically memory T cells, then it may explain why we
did not observe a reduction in clinical disease when P-EAE mice were treated with
CBD. In an attempt to address the first question involving disease robustness, we
decided to increase the dose of CBD to 150mg/kg to see if higher levels of CBD would
be more effective in the P-EAE model. Unfortunately, during these experiments, which
were conducted with the younger mice, we were unable to induce disease in the WT
mice. This led us to wonder why we had 100% incidence of disease during the first two
studies and had 0% incidence in a third study.
After reviewing our methodology for all three experiments, it was determined that
one of the major differences between the first two experiments and the third was the
age of the 2D2 mice. The 2D2 mice from the first two experiments had been allowed to
age for approximately 6 months before they were used to induce P-EAE, and in the third
set of experiments the mice were only 10 weeks of age when they were used. With this
in mind, additional experiments were performed to confirm whether or not 6 month old
mice induced more severe P-EAE as compared to 10 week old mice, and to identify
potential differences in the transgenic T cell population after 2D2 mice are injected with
MOG35-55 peptide. An additional four rounds of P-EAE were performed for this set of
experiments, with two rounds using mice 10 weeks of age and two rounds using mice 6
month of age. Interestingly, while the clinical scores from these studies did show
significantly higher disease in P-EAE induced with older 2D2 mice, the time of onset for
the latter experiments did not match the time of onset for the experiments performed
with CBD. One possible explanation for this discrepancy is that the treatments given to
the mice in the first studies expedited disease progression in the mice which received
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cells from the 6 month old 2D2 mice, and suppressed disease in mice which received
cells from the 10 week old mice. Moreover, since this observation occurred in both the
CO and CBD groups we suspect CO to be the cause of the discrepancy. However,
despite these differences, the significantly higher clinical scores observed in older mice
in the later rounds of experiments did confirm that 6 month old mice were more capable
of inducing clinical disease as compared to 10 week old mice.
To examine differences between the transgenic T cells in these mice 11 days
after the initiation of active EAE, we chose to include central memory T cells, effector
memory T cells, and IFN-γ producing T cells in our analyses based on a previous study
by Williams et al. which used 2D2 mice to show effector memory Th1 cells played an
important role in the induction of P-EAE [89]. The results from the present study strongly
suggest a difference between the memory T cell response of younger 2D2 mice and
older 2D2 mice to MOG35-55 peptide. More specifically, we found that there was an initial
memory response in the older mice which shifted the balance of central and effector
memory T cells to favor the effector memory phenotype in both the spleens and lymph
nodes. However, once these cell populations were cultured, the effector memory T cell
population did increase in younger mice. Additionally, we found that splenocytes from
older mice had higher percentages of IFN-γ producing T cells after culture as compared
to 10 week old mice. While we did not actually stain for IFN-γ production in memory T
cells, considering the extremely high percentage of effector memory T cells in the
transgenic T cell pool, the data suggests that the higher percentage of IFN-γ producing
T cells in the transgenic T cell population of 6 month old mice likely represents an
increase in the functional abilities of the effector memory T cells derived from the
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spleens of these mice as compared to younger mice. Taken together, these results
show a higher percentage of transgenic effector memory T cells isolated from older
mice, which appear to show higher functional capabilities as measured by IFN-γ
production. Based on the results from previous studies it is likely that this population is
responsible for the increased clinical scores produced when P-EAE is induced with
older mice [89]. It should also be noted that a significantly higher number of Th17 cells
were found in the spleens and lymph nodes of younger mice as compared to older
mice. However, considering the low numbers of Th17 cells that were recovered after the
72hr culture, and that Williams et al. found transgenic Th17 cells to be less capable of
transferring disease than Th1 cells, we do not think the increase in Th17 cells found in
young mice contributed significantly to disease progression in the present study [89].
In addition to the differences observed in memory T cells, we also found that
fewer cells were recovered from spleens and lymph nodes of older 2D2 mice (results
not shown) and that the percentage of transgenic T cells was lower in older mice as
compared to younger mice. Initially this seemed counterintuitive, since we expected to
see a more robust response from the transgenic T cells of older mice. However, when
we considered these results in light of the results of the B cell stain, we realized that the
lower percentage of transgenic T cells found in the spleens and lymph nodes of older
mice likely represents a more balanced immune response in these mice. However,
since the primary focus of this study was on the functional response of transgenic T
cells in 2D2 mice, we did not stain for B cell prior to culture, which is when the greatest
difference was seen between young and old mice with respect to transgenic T cell
percentages. It would be interesting to explore this further in future studies to see if the
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B cell response of 2D2 mice was enhanced in older mice before culture, which would
suggest that the immune response in older mice develops beyond the initial T cell
responsiveness that is inherited as part of the transgenic nature of these mice.
One final population of cells we chose to look at was the double negative T
cells. Initially we suspected that we would find a population of transgenic T cells that
were under chronic stimulation in vivo, and thus would have adopted the double
negative phenotype similar to those found in a previous study [90]. However, we found
no such population within either set of mice. The results from the double negative stain
performed after restimulation of transgenic T cells concluded that double negative cells
were not responsible for the increased clinical disease seen when P-EAE was initiated
with cells from older 2D2 mice.
5.2.4

Conclusion
This study represents an important advancement in our understanding of how the

immune system ages. Here we show a functional difference in the memory response of
T cells between mice of different ages in the context of the P-EAE model. This model is
commonly used to study MS, a disease in which patients gradually accumulate
neurologic dysfunction with age and which does not show clinical symptoms until 20-30
years of age [14, 19, 89, 91]. The difference shown in this study suggests that even
when 2D2 mice have not manifested clinical disease prior to administration of MOG35-55
peptide, there are fundamental changes occurring in their responsiveness to MOG 35-55
peptide. We believe this represent an important model that can be used to understand
how the immune system evolves in MS patients even prior to the initial onset of clinical
symptoms, and as the patient ages.
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